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Zusammenfassung 
Das hämolytisch-urämische Syndrom (HUS) ist eine Krankheit, die sich bei den meisten 
Patienten im Kindes- und Jugendalter manifestiert. Das HUS zeichnet sich durch die Trias 
hämolytische Anämie, Thrombozytopenie und akute Niereninsuffizienz aus. Histologisch und 
pathopysiologisch liegt der Erkrankung eine thrombotische Mikroangiopathie (TMA) zu 
Grunde. Hierbei kommt es zur Schädigung der Endothelzellen und zur Bildung thrombotischer 
Verschlüsse in den kleinen Gefässen, insbesondere in den Nieren. Das HUS ist jedoch eine 
Systemerkrankung; daher treten schwerwiegende Komplikationen auch in anderen Organen 
auf wie z.B. Gehirn, Augen, Herz, Pankreas. 
Historisch wurde das HUS in Durchfall-positives HUS (sog. „typisches“ HUS) und Durchfall-
negatives HUS (sog. „atypisches“ HUS) eingeteilt. Im ersten Fall wird das HUS durch 
Infektionen mit Shigatoxin-produzierenden Escherichia coli (STEC) verursacht. Das 
„atypische“ HUS, das die rezidivierende HUS Formen beinhaltet, ist STEC negativ. Im Laufe 
der letzten Jahrzehnte wurde die HUS Klassifikation mit neu gewonnenen 
pathophysiologischen Erkenntnissen fortlaufend geändert und an die Vielfalt der HUS-
Ursachen angepasst. Insbesondere die Rolle des Komplementsystems in diesem 
Krankheitsbild prägt die aktuelle HUS-Klassifikation: Infekt-assoziiertes HUS (u.a. STEC, 
Pneumokokken, andere Infektionen), atypisches HUS (genetisch determinierte Dysregulation 
des alternativen Komplementsystems), HUS bei Cobalamin (C) Defekt und HUS assoziiert mit 
anderen Systemerkrankungen (z.B. autoimmun Erkrankungen, Organtransplantation, 
Tumoren). 
Auf Grund der Seltenheit und der Vielfältigkeit des HUS ist die Durchführung von doppelblind 
kontrollierten klinischen Studien kaum möglich. Es gibt einige Langzeitstudien betreffend 
Mortalität und Nierenfunktion. Aber genaue Daten zum neurologischen und kognitiven 
Outcome sowie der Lebensqualität von Kindern nach HUS fehlen. Daher gewinnen klinische 
Outcome-Studien und Fallserien bei diesem seltenen Krankheitsbild einen besonderen 
Stellenwert, um experimentelle Erkenntnisse besser verstehen und erweitern zu können.  
Mit dieser Arbeit möchte ich deshalb anhand von Outcome-Studien einen klinischen Ansatz 
zur Erfassung sowie zur Optimierung der Lebensqualität betroffener Kinder und deren Eltern 
nach lebensbedrohlichem HUS vorstellen. Zudem soll diese Arbeit zeigen, wie in den letzten 
Jahren auf dem Gebiet der thrombotischen Mikroangiopathie neue Perspektiven für das 
Verständnis der Pathophysiologie und für neue Therapieoptionen sowohl für das HUS, aber 
auch für andere Glomerulopathien eröffnet wurden. Obwohl das HUS bisher vor allem als 
pädiatrische Entität verstanden wurde, konnten in den letzten Jahrzenten neue Erkenntnisse 
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insbesondere im Bereich des Komplementsystems für die Diagnose und Therapie von 
Krankheiten gewonnen werden, die vorwiegend in der Adult-Nephrologie auftreten wie z.B. 
membranoproliferative Glomerulonephritis und weitere Glomerulopathien (assoziiert mit 
Schwangerschaften, Medikamenten, Systemerkrankungen u.a.). Zudem können renale 
Langzeitkomplikationen (u.a. Proteinurie, Hypertonie, Niereninsuffizienz) auch erst nach 
einem längeren „freien“ Intervall im erwachsenen Alter auftreten. Deshalb ist eine formelle 
Transition und kontinuierliche nephrologische Betreuung dieser Patienten erforderlich ist. 
Mit den klinischen Studien bei Kindern mit HUS (original articles 1-3) haben wir im ersten Teil 
sowohl die akuten neurologischen Komplikationen, als auch den neurologischen und 
kognitiven Langzeitverlauf erfasst. Im zweiten Teil wurden die Lebensqualität und die 
psychologische Anpassung der Patienten analysiert. Im dritten Teil wurde die Lebensqualität 
und psychische Verfassung der Eltern von Kindern nach durchlebtem HUS untersucht.  
Die therapeutisch-klinische Studie (original article 4) beschreibt anhand einer klinischen 
Fallserie die Beteiligung des alternativen Komplementsystems bei der membranoproliferativen 
Glomerulonephritis und C3-Glomerulopathie. Wie beim HUS können auch bei diesen 
Krankheiten Genmutationen von Komplementfaktoren gefunden werden, welche zur 
Dysregulation des alternativen Komplementsystems führen. Entsprechend kann wie beim 
HUS eine komplementregulierende Therapie erfolgreich eingesetzt werden. 
Summary 
The haemolytic uremic syndrome (HUS) is a disease syndrome presenting mainly in childhood 
and adolescence. It is characterized by the triad of haemolytic anemia, thrombocytopenia and 
acute renal failure. Histology and pathophysiology demonstrate a thrombotic microangiopathy 
(TMA) which leads to damage of endothelial cells and to the formation of thrombotic occlusions 
in small vessels, in particular in the kidneys. HUS, however, is a systemic condition with 
complications occurring in other organs including e.g. brain, heart, eyes and pancreas. 
Historically, HUS has been classified into diarrhea-positive HUS (so- called “typical” HUS) and 
diarrhea-negative HUS (so-called “atypical” HUS). In the former, HUS is predominantly caused 
by infections with Shiga toxin-producing Escherichia coli (STEC), while “atypical” HUS, with 
recurrent HUS episodes, is STEC negative. Over the last decades, the HUS classification was 
updated continuously, given new pathophysiological findings, and therefore has been adapted 
to the variety of HUS causes. Particularly, the role of complement system in this disease 
underpins the current HUS classification: infection-associated HUS (including STEC, 
pneumococcal, other infections), atypical HUS (genetically determined dysregulation of the 
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alternative complement system), Cobalamin (C) defects and HUS associated with other 
systemic diseases (e.g. autoimmune diseases, organ transplantation, malignancies) 
Due to the rarity, the variability and severity of this disease, and for ethical-moral reasons, the 
performance of double-blind, controlled studies is hardly possible. Consequently, well-
validated long-term data on the neurological, cognitive outcome and quality of life of children 
after HUS are scarce. Knowledge of clinical outcomes in studies and case series are of 
particular importance to inform this rare clinical picture, in order to reach a better understanding 
and to expand research knowledge.  
Based on the new translational perspectives described in recent years in the field of thrombotic 
microangiopathy leading to a better understanding also of other glomerulopathies, new 
therapeutic options, will be discussed. Although HUS has thus far been a primarily pediatric 
entity, in recent decades new insights have been gained, particularly in the field of the 
complement system, in forming diagnosis and treatment of diseases that predominantly occur 
in adult nephrology including membranoproliferative glomerulonephritis and other 
glomerulopathies (e.g associated to pregnancy, to drugs, to systemic diseases). In addition, 
renal long-term complications after HUS (including. proteinuria, hypertension, renal 
insufficiency) can manifest at adult age, therefore a nephrology care across the life-course of 
these patients is required. 
 
Here, I present a clinical approach for detection and optimization of the quality of life in affected 
children and their parents after life-threatening HUS. In the first part of the clinical studies 
(original article 1-3), both the neurological complications as well as the neurological and 
cognitive long-term course in children after HUS were recorded. In this context, in a second 
part, the quality of life and psychological adjustment in children after HUS by applying 
standardized questionnaires, were assessed. Simultaneously, the quality of life and mental 
health of the parents of children who survived HUS, were analyzed. 
A therapeutic-clinical study (original article 4) describes the involvement of the alternative 
complement system in membranoproliferative glomerulonephritis and C3 glomerulopathy 
based on the experience of a case series. As in HUS, also in these glomerulopathies mutations 
of complement factors leading to dysregulation of the alternative complement system are 
involved. Therefore, as in HUS a complement regulation therapy may be possible also for other 
glomerulopathies,  
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Introduction
 
Haemolytic uremic syndrome: from Zurich to worldwide renown  
In 1924, Eli Moschcowitz, an American internist of Hungarian origin, was the first to describe 
a new clinico-pathological entity obeserved in the autopsy of a young woman who died after 
developing acute febrile haemolytic anemia with petechiae and neurological signs (mild left 
hemiparesis and facial paralysis). He described the unique clinical and post mortem 
histological features and named the disease thrombotic thrombocytopenic purpura (TTP) 
(Moschcowitz E 1924). Three decades later, in 1952, William St. C. Symmers, a pathologist at 
the Charing Cross Hospital in London, coined the term thrombotic microangiopathy (TMA) to 
indicate the location and the most striking characteristic features of the histological lesions: 
widely disseminated thrombosis of the smallest-caliber blood vessels, with endothelial 
hyperplasia, important dilatation of the affected vessels, an no inflammatory reaction. Close 
collaboration with Symmers led Conrad Gasser, a Swiss paediatric haematologist at the 
Kinderspital Zurich, to describe a new entity ‘haemolytic uraemic syndromes’ (HUSs) in 1955. 
He reported five children with microangiopathic haemolytic anaemia, thrombocytopenia, and 
acute renal failure. Two each of the patients had prodromal diarrhea and pleuropneumonia; 
one patient had no prodromes (Gasser C 1955). The plural form of HUS (‘Syndrome’ in 
German) was deliberately used in anticipation of the epidemiological, clinical, and 
pathophysiological heterogeneity of the disease. Contrary to TTP, severe renal involvement is 
a hallmark of HUS. 
Over the last 10 years many advances have been made in the field of HUS. New pathogenic 
mechanisms have been identified (e.g genetic or acquired dysregulation of the alternative 
complement pathway) and innovative effective treatment has become available. The 
classification of HUS has been adapted several times in the last years. In 1998 the current 
classification was divided into the typical diarrhea associated HUS due to infection from shiga 
toxin-producing Escherichia coli (STEC), and atypical HUS, with the latter having a more 
severe, and in some cases relapsing course. The current classification of HUS considers 
various forms of HUS which can occur as complication of, or be precipitated by, various 
diseases and conditions as described in figure 1. 
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Classification of various forms of haemolytic uremic syndrome 
 
Figure 1: From Fakhouri F; Lancet 2017 
 
The incidence of HUS in central Europe is estimated to be 1 to 1.5 patients/ 100 000 children 
and adolescents under 16 years. In Switzerland approximately 20 HUS-cases occur every year 
as reported by the Swiss Paediatric Surveillance Unit in a prospective national study (Schifferli 
A 2010). In this registry, typical, diarrhea- associated HUS occurred in 90% of the children and 
STEC was isolated in 60% of the tested blood samples. The mortality rate was 5.3% with the 
highest mortality in pneumococcal-associated HUS. The severity of thrombocytopenia and the 
presence of central nervous system involvement significantly correlated with mortality.  
Children aged one to five years are most by affected, however this disease can occur at any 
age, with a peak in the second and third year of life. In Switzerland HUS is the most common 
cause of acute kidney injury (AKI) requiring renal replacement treatment in childhood. Mortality 
is low, but the rate of long-term renal and extrarenal complications, i.e., proteinuria, 
hypertension and chronic kidney disease is significant. 
 
 
 
STEC=Shigatoxin-
producing Escherichia coli 
DGKE=diglycerolkinaseε 
CFH=complement factor H 
CFI=complement factor I 
MCP=membane-cofactor 
protein 
C3=complement C3 
CFB=complement factor B 
THBD=thrombomodulin 
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Classification of thrombotic microangiopathy (TMA)  
TMA reflects the unifying histopathological description, encompassing both TTP and HUS, 
clinically characterized by thrombocytopenia, microangiopathic haemolytic anemia and organ 
injury (Moake JL 2002). Acute kidney injury and neurological symptoms are common and 
prominent feature because of the vulnerability of the glomerular and brain circulations to 
endothelial damage and occlusion. TMA is associated with significant mortality and morbidity, 
including end stage renal disease (ESRD); however, prompt initiation of supportive and 
specific management can alter outcome (George JN 2014). 
The classification of TMAs is challenging and constantly evolving. Historical diagnostic 
classifications were based on clinical findings: TTP when neurologic involvement 
predominated and HUS when kidney disease was predominant. Therefore, until the late 
nineties, confusion between TTP and HUS persisted (some authors referred to the syndrome 
as HUS/TTP). Classifications have evolved as understanding of the molecular basis of disease 
has improved: TTP is defined by a severe congenital or acquired ADAMTS13 deficiency, 
Diarrhea-associated HUS is defined by the presence of Shiga toxin-producing E. coli (STEC-
HUS), and atypical HUS (aHUS) is used for other causes of TMA. The discovery of the role of 
complement in patients with aHUS has subsequently led to the term complement-mediated 
TMA (George JN 2014; Nester C 2015). Inconsistencies in the historical and current literature 
over nomenclature make interpretation difficult: aHUS may refer specifically to complement-
mediated TMA, or be more generally applied to any TMA that is not TTP or STEC-HUS. In the 
recent literature (Brocklebank V et al 2018), the term complement-mediated aHUS is used 
when the cause is defined as such, and the term aHUS is used when the cause is ill-defined. 
Current classifications describe primary TMAs, either acquired or congenital (e.g. complement 
mutations, ADAMTS 13 mutations), secondary TMAs, and infection-associated TMAs (figure 
2). 
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Figure 2: From Brocklebank V; CJASN Feb 2018 
Current classification define primary TMAs as hereditary or acquired, or autoantibodies to complement H. 
Secondary TMAs occur in a spectrum of conditions and in many cases the pathogenic mechanism are multifactorial 
or unknown. TMAs may be also associated with various infections as STEC and pneumococcal HUS. In other 
infections, the processes are not defined and in some cases the infection may trigger manifestation of primary TMA. 
 
These terms are however too simplistic as they do not account for the increasing recognition 
that patients with an underlying complement risk factor often require a secondary trigger for 
TMA to manifest. Mutations in the genes of complement factor proteins have been found in 
about 60% of patients with the atypical form of HUS (aHUS). 
The role of the innate Immune system and the complement cascade  
Humans are permanently exposed to micro-organisms and could not exist as species without 
a highly effective mechanism of host defense. The innate immune system constitutes the first-
line barrier to prevent microbial invasion. Its components are inherited from parent to child and 
are directed against molecules expressed only by micro-organisms. The term „innate“ 
immunity refers to immune responses that are present from birth. This is in contrast to the 
“adaptive” immune system which is based on up-regulation, adaption and repeated boostering 
as a result of recurrent and/or constant exposures to micro-organism. Considering the 
temporal aspect, there is a difference between the two immune systems: the response time of 
the „innate“ immune system the pathogens is 20 to 30 minutes, whereas the development of 
a specific “adaptive” immune response mediated by T-cells and antibodies takes days to 
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weeks. Therefore, the innate immune system protects the host from the time of microbe 
exposure to elaboration of the adaptive responses. 
The complement system constitutes an essential part of the innate immune system. It guards 
the host’s intravascular space by opsonizing and lysing bacteria. In addition, it promotes the 
local acute inflammatory response, which in turn instructs and influences the adaptive immune 
response.  
The complement system is a proteolytic cascade, comprising more than 30 proteins, where 
serine proteases activate each other in a strictly ordered manner. The complement 
components exist in soluble form called the fluid phase, or are expressed on the cell 
membrane, the solid phase (Angioi A 2015). The plasma proteins interact via three major 
cascades: the classical, the lectin and the alternative pathways. Each of the 3 complement 
pathways is triggered by a distinct set of conditions (e.g. antibodies binding to antigens, sugar 
molecules on the surface of pathogens or damaged host cells, respectively). All three pathways 
generate a proinflammatory environment, with the common goal of modifying the target 
membrane by deposition of C3 activation products (opsonization) and then engaging a 
common terminal sequence or pathway called the « membrane attack complex » (MAC) which 
leads to membrane perturbation and cell lysis. The successive phases include attachment 
(initiation phase after “stimuli”), activation and amplification (amplification phase/convertase 
formation), and membrane attack (effector phase/membrane perturbation) (Angioi A 2016). 
Rigorous active control mechanisms are required to prevent damage to self (figure 3). 
The classical pathway is most commonly triggered by antibodies binding to antigens. This 
pathway is activated by interaction between C1q and immune complexes (immunoglobulin G 
or immunoglobulin M). The serine proteases C1r and C1s are then activated by binding to the 
C1q-immunoglobulin complex. This, triggers an autoactivated cleavage process leading to 
amplification of complement components (C4, C4a, C4b, C2, C2a, C2b). The C4b fragment 
combines with the lipid bilayer of the target cell and C2a to form the C3 convertase of the 
classical pathway, C4b2a. 
The lectin pathway, also called the mannan-or mannose-binding pathway, is similar to the 
classical pathway, and generates an identical C3 convertase (C4b2a). Lectins are proteins that 
bind to sugars. Mannose-binding-lectin (MBL) is part of the acute-phase response.  MBL binds 
to MBL-associated serine proteases (MASP-1, MASP2) that cleave intact C4 and C2 to 
generate the C4b2a convertase).  
The alternative pathway is an ancient pathway of innate immunity preceding adaptive 
immunity. Thus, the alternative pathway does not require antibodies or prior contact with 
microbes to function and become activated. It serves as an independent immune system, 
capable of recognizing and destroying infectious elements. In contrast to the classical and 
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lectin pathways, the alternative pathway (AP) is capable of autoactivation. Indeed, C3 is 
constantly autoactivated (so-called « C3 tickover ») at a low level. This process is rapidly 
amplified in the presence of microbes, damage to host cell, or when complement regulatory 
proteins are deficient. Deposition of C3b on target cells can be efficiently amplified by the 
alternative pathway’s feedback loop (figure 3 and figure 4). 
 
  
Figure 3: From Angioi A; Kidney Int 2016 
 
In summary, the alternative system is a complex-interacting system which is engaged when 
activated C3 binds factor B. Bound factor B undergoes proteolytic cleavage mediated by 
another serine protease, factor D (FD), to produce the fragments Bb and Ba which are released 
into the surrounding milieu (Forneis F 2010). The alternative pathway C3 convertase, C3bBb, 
is then stabilized by properdin (P), creating the complex C3bBbP. As the convertase cleaves 
more C3 to C3b, an amplification loop is set in motion, resulting in the deposition of large 
amounts of C3b on the target cells (figure 3). 
C3b, deposited by the classical or lectin pathway, can serve as a nidus for amplification by the 
alternative pathway. In many clinical situations, the initial deposition of C3b is mediated by the 
classical or lectin pathways. The C3b is then amplified many-fold through the feedback loop of 
the alternative pathway. 
Finally, the alternative pathway also engages the MAC which is then assembled as in the 
classical pathway.  
AP = alternative pathway 
CP = classical pathway 
 
12 
 
During complement activation, host cells are protected from damage by plasma and 
membrane regulatory proteins (complement factor I (FI), complement factor H (FH), MCP, 
decay-acceleration factor (DAF), complement factor H related proteins (FHRPs) (figure 3). 
Therefore, it is essential to understand the role of complement in the normal physiological 
setting in maintaining homeostasis and keeping the organism intact and healthy. 
Consequently, inappropriate timing, dysregulation, misdirected delivery of complement 
effector products or any effect that disturbs the delicate balance of this complex network of 
interacting proteins can result in pathology and in numerous diseases, such as ischemia 
reperfusion injury, Systemic Lupus Erythematodes (SLE), and others (Zipfel PF 2009). 
In HUS, platelet dysfunction and damage of the endothelial cell lining of kidney blood vessels 
are primary events that result in microvascular lesions and in the formation of microthrombi 
occluding the small blood vessels in the kidney (figure 4).  
Complement pathway, its regulators and formation of microthrombi in TMA  
 
 
Alternative Pathway 
Figure 4: Adapted from Brocklebank V CJASN Feb 2018 and Liszewski MK, Immunology Scope Monograph 1992 
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Biochemical and genetic abnormalities in HUS and TMA 
The defining laboratory features of HUS include the triad of: 1) microangiopathic haemolytic 
anemia, identified by erythrocyte fragmentation on peripheral blood film microscopy, caused 
by a turbulent flow in the microcirculation due to partial occlusion by platelet aggregates, 
elevated lactate dehydrogenase as a result of cell lysis and tissue ischemia, reduced 
haptoglobin and a negative direct antiglobulin (Coombs) test (except in pneumococcal HUS);  
2) thrombocytopenia resulting from platelet aggregation and consumption; 3) acute kidney 
injury. The renal microcirculation has a high shear stress and turbulent flow making it 
vulnerable to thrombotic microangiopathy (Bettoni S 2017). The kidneys therefore are usually 
the first organ affected by complications in HUS. Once TMA is demonstrated by the above 
mentioned routine biochemical and haematological analysis, further investigations are aimed 
at determining the underlying disease cause. In this setting, genetic investigation of 
complement disorders may be crucial to make an accurate diagnosis (Table 1). 
As described above, the complement system is tightly regulated by the circulating plasma “fluid 
phase regulator proteins”, mainly produced in the liver, including e.g. complement Factor H 
(CFH) and factor I (CFI), and cell surface “membrane-bound regulator proteins” such as 
membrane cofactor protein (CD46).  
Defects in these regulators or in the alternative pathway components, associated with either 
increased or impaired activity, can lead to complement dysregulation, activation of the terminal 
complement pathway, generation of the anaphylatoxin C5a and the membrane attack complex 
(C5b-9), finally resulting in complement-mediated aHUS. 
In complement–mediated aHUS, dysregulated complement activation occurs primarily on the 
endothelial cell surface, and although abnormal serum levels of complement components, 
such as low C3 may be observed, normal levels do not exclude complement-mediated disease 
(Goodship Th 2017; Kavanagh D 2013). Molecular evidence that CFH mutations are 
associated with aHUS was first described in 1998 (Warwicker P et al 1998). Since then several 
studies have shown numerous heterozygous pathogenic activating mutations in the genes 
encoding the alternative pathway components C3 and factor B, and loss-of-function mutations 
in the genes encoding the regulators FH (including CFH/CFHR -- complement factor H-related 
-- fusions) and FI, and CD46 (Kavanagh D 2013). These genetic mutations are not causative, 
but instead predispose to HUS, with incomplete penetrance. The penetrance of disease is age-
related and has been reported to be as high as 64% by the age of 70 years for individuals 
carrying a single genetic mutation. This observation highlights that additional disease risk 
modifiers are essential. Approximately 3% of patients have more than one mutation in the 
complement system genes, with increased penetrance per additional mutation. Haplotypes 
(particular combinations of single nucleotide polymorphisms) in CFH and CD46 also modify 
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penetrance (Fakhouri F 2017; Fremeaux-Bacchi 2013). Atypical HUS is also often associated 
with high risk of disease recurrence after renal transplantation. However, a combination of 
certain heterozygous mutations (e.g. MCP/CFI) might have a beneficial impact on the course 
after renal transplantation, predicting a lower risk of aHUS recurrence in the renal graft (Pabst 
WL et al 2013). Together, these observations do not answer the question why some individuals 
never develop the disease or do so only in later life. Such variability might be explained by the 
need for a second hit, e.g., an environmental trigger such as pregnancy or infection which may 
unmask a latent complement defect. Complement activation is a common factor in many of 
these triggering events. Atypical HUS associated with autoantibodies against FH was first 
reported in 2005 (Dragon-Durey MA 2005). Moreover, functional analyses have demonstrated 
a disruption of complement regulation by multiple mechanisms (Blanc C 2012). A strong 
association of CFH-antibodies to homozygous deletion of CFHR3 and CFHR1, enconding the 
proteins FHR3 and FHR1 is described, although the mechanism is not understood; CFHR3/1 
deletion is a common polymorphism, but is not present in all individuals who develop CFH 
autoantibodies (Brocklebank V 2017). This form of aHUS predominantly presents in childhood, 
frequently with a gastrointestinal prodrome. Autoantibodies against FI have also been 
reported, but they are rare and their functional relevance remains to be established (Kavanagh 
D 2012). Also genetic variants in thrombomodulin (THBD) have been reported in association 
with aHUS (Delvaeye M 2009). In pneumococcal HUS, involvement of a vitronectin-binding 
adhesin of serotype 3 pneumococci binding to CFH was recently suggested, leading to 
activation of the complement cascade and HUS (Kohler S 2015). 
Recently, interaction between von Willebrand factor (VWF) and complement has been 
described (Bettoni S 2017). ADAMTS 13 is a metalloproteinase cleaving ultralarge (UL-) VWF 
multimers into numerous small fragments on the surface of endothelial cells. In congenital TTP 
(ADAMTS 13 deficiency) or in acquired TTP (anti-ADAMTS 13 antibodies), VWF multimers 
cannot be cleaved because of ADAMTS 13 deficiency. Therefore, in the absence of ADAMTS 
13 the endothelium is exposed to abundant deposition of unfractionated VWF multimers 
resulting in increased thrombogenicity. Consequently, activated complement system is leading 
to microvascular injury of endothelial cells and to TMA.  
Recessive mutations in diacylglycerol kinase (DGKE) may result in protein kinase C activation, 
leading to upregulation of VWF and tissue factor resulting in a prothrombotic state and inducing 
TMA (Lemaire M 2013). The outcomes of TTP and HUS treatment strategies have been 
inconsistent in DGKE-induced HUS (Brocklebank V 2017). 
 
15 
 
 
 
Genetic complement investigation in 
TMA (HUS/TTP) 
 
Table 1 
Clinical features and complications in HUS and TMA 
The clinical presentation of HUS is common also for TMA, reflecting haemolysis and ischemic 
organ dysfunction, and depends on the underlying disease etiology: acute kidney injury is 
therefore a common manifestation in TMA although rarely a severe feature of TTP. Extrarenal 
manifestations do occur in aHUS and STEC-HUS, however it is not known whether they are a 
consequence of the TMA, a direct effect of complement activation or shiga toxin, or 
complications of AKI, such as severe hypertension and uremia. 
Extrarenal complications have been reported in 19-26% of the HUS cases (Schifferli A 2010; 
Mattheis J 2016). The clinical presentation varies from mild disease to fulminant course, 
including death. 
Extrarenal complications:  
• Neurological involvement: e.g. seizures, altered consciousness, cerebral haemorrhage, 
encephalopathy 
• Gastrointestinal involvement: e.g. diarrhea, vomiting, abdominal pain, intussusception, 
bowel obstruction, sclerosing cholangitis, hepatocellular cholestasis, pancreatitis, diabetes 
mellitus 
• Cardio-vascular involvement:  cardiomyopathy, cerebral arterial thrombosis/stenosis, 
extracerebral artery stenosis, myocardial infarction, digital gangrene/ skin necrosis 
• Ocular involvement: isolated intraretinal haemorrhages, Purtscher-like retinopathy with 
retinal ischaemia, visual impairment 
• Pulmonary involvement 
 
New therapeutic options 
The use of eculizumab in complement-mediated HUS based on pathophysiology and in -
selected cases of - STEC-HUS, has permitted more rapid and specific treatment in recent 
years, especially in cases with severe neurological complications.  
• CFH, anti-CFH-Ab and CFHR 1-5,  
• CFI 
• CFB 
• C3 
• Thrombomodulin 
• MCP/CD46  
• DGKE 
• ADAMTS 13 and Anti-ADAMTS 13 antibody (Ab) 
• Cobalamin-C defect 
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Eculizumab is therefore considered first-line treatment if a complement-mediated aHUS is 
suspected and TTP has been excluded. In the pre-eculizumab era, one option for individuals 
with a defect in a complement protein predominantly synthesized in the liver (CFH, CFI CFB 
and C3) who had developed ESRD was combined liver and kidney transplantation (Saland J 
2014). However, this procedure was associated with significant perioperative complications 
and mortality. Therefore, long-term treatment with parenteral eculizumab in complement-
mediated HUS has revolutionized the therapeutic approach and improved the outcome. In 
addition, knowledge gained from treatment of complement-mediated HUS, has led to the use 
of this complement- modifying/inhibiting therapy for other causes of TMAs. 
Elucidation of the central role of primary complement defects in the pathogenesis of aHUS 
provided the mechanistic rationale for treating complement-mediated aHUS with complement 
–inhibiting therapy. Eculizumab is a recombinant humanized antibody that functionally blocks 
C5, and seminal trials published in 2013 demonstrated its excellent efficacy (Legendre CM 
2013). Although these were single-arm studies rather than randomized, controlled trials, the 
historically poor outcomes of aHUS justified such study designs. In prospective trials, complete 
TMA response was achieved in approximately 65% of patients after 26 weeks of eculizumab 
therapy in both adults (Legendre CM, 2013) and children (Greenbaum LA 2016) 
With increasing clinical use however, evidence is emerging of nonresponse to eculizumab in 
aHUS. A recent clinical trial of Greenbaum et al (Greenbaum LA 2016) highlighted that, those 
with a rare genetic variant in the complement system or autoantibodies to complement factor 
H, all had an improvement in estimated glomerular filtration rate (eGFR), whereas 27% of 
individuals without an identified complement abnormality failed to show any improvement. It is 
not clear whether this lack of response reflects a non-reversible organ damage or true 
nonresponse.  
The role of complement activation as a second- hit amplifying endothelial cell damage in TMA 
is suggested in STEC and pneumococcal- induced HUS, as well as in several secondary forms 
of TMA. 
Typical, STEC-HUS is caused by verotoxin (Shiga toxin (Stx)) released by bacteria (e.g. E. 
coli, Shigella), which can be detected in stool samples by PCR. The toxin is absorbed by the 
gut, reaches the circulation, and leads to alteration of the endothelium of the microcirculation, 
thereby triggering the alternative complement pathway, resulting in the formation of 
microthrombi in end-organs (figure 5). 
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Figure 5: From Fakhouri F, Lancet 2017. In STEC-HUS, Stx enters the endothelial cell via Globotriasylceramide 
(Gb3)-dependent and Gb3-independent pathways, and exerts its cytotoxic effect via protein synthesis inhibition and 
enhancement of the CXCR4/CXCR7/SDF1 pathway. CXCR4/CXCR7 are 2 G-protein-coupled receptors and there 
are shared cognate chemokine ligand (SDFI=stroma cell derived factor1) as key target of Stx-induced mRNA 
expression. Stx also induces the translocation of P-selectin (a cell adhesion receptor) to the endothelial cell surface, 
favouring the assembly of alternative C3 convertase, the release of C3a and thrombomodulin (TM). 
Renewed interest in HUS arose during the severe outbreak in Germany in 2011 (Kielstein JT 
2011). In a retrospective registry analysis the various therapies applied during outbreak were 
compared (supportive care, plasmapheresis and eculizumab). Despite frequent renal 
impairment, advanced neurological disorders and severe respiratory failure, short-term 
outcome was better than expected when compared with previous reports. However, given the 
retrospective non-randomized nature of the intervention and analysis, no evidence-based 
indication for eculizumab in STEC could be established. Latter was also confirmed recently by 
Loos et al (Loos S 2018), indicating the need for a randomized controlled study in STEC-HUS 
before a treatment with eculizumab can be recommended. This therapy however seems to be 
supported by recently published experimental data also suggesting involvement of the 
complement pathway in the typical HUS form. 
The majority of follow-up studies of children with HUS have focused on renal outcome after 
HUS episode. Data on neurological complications and neurodevelopmental/cognitive outcome 
in children, but also psychological outcome in children and their parents’ after HUS, however, 
are scarce. Therefore, well-validated long-term data in this field are needed, resulting in the 
studies described below (original article 1-3). 
  
18 
 
Original article 1: Neurodevelopmental long-term outcome in children after haemolytic 
uremic syndrome 
 
Kathrin Buder, Beatrice Latal, Samuel Nef, Thomas J. Neuhaus, Guido F. Laube, Giuseppina 
Spartà 
 
Pediatr Nephrol. 2015; 30(3):503-13. 
(Buder et al 2015) 
 
In this study we recruited 47 children from a sample of 129 patients treated for HUS in the 
Paediatric Nephrology Unit of the Zurich University Children’s Hospital between April 1995 and 
February 2013. We investigated the long-term neurodevelopmental outcome in children with a 
history of both typical infection-induced HUS and atypical HUS. Thus, we compared the 
outcomes of central nervous system involvement (CNS) in HUS. 
First, we collected the clinical and demographic data from patients’ records, evaluated risk 
factors and analysed them retrospectively, in a cross-sectional study design. Clinical 
parameters were obtained from medical records (sex, age at disease, renal function, anuria, 
requirement of dialysis and CNS involvement during acute phase of HUS) as well as data on 
other comorbidities and ESRD with renal replacement therapy at follow-up.  
Second, we assessed neurodevelopmental outcomes including intellectual and neuromotor 
performance and conducted a standardized neurological examination. 
We examined 47 children with a previous diagnosis of HUS aged between 6 years and 16 
years 11 months. The median follow-up was 7.8 years after the first episode of HUS (range 
0.4-15.5) and the median age of the children at examination was 10.6 years (range 6-16.9).  
 
This study revealed an overall favourable cognitive outcome, with the intellectual quotient (IQ) 
of the whole study population falling within the normal range (Wechsler D 2002). However, the 
neuromotor performance was significantly poorer in the neuromotor performance domains 
“adaptive fine”, “gross motor”, “static balance” and “associated movements”. Abnormal 
neurological findings were present in 34% of the children during acute HUS. However, 
subsequent neurodevelopmental outcome was not significantly different between children with 
or without CNS involvement. Studies reporting neurodevelopmental outcomes in children after 
HUS with CNS involvement are scarce. This study focused on the long-term intellectual and 
neuromotor performance of children after HUS and represents an important step in better 
defining the long-term prognosis of this severe disease.  
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Original article 2: Long-term health-related quality of life and psychological adjustment 
in children after haemolytic-uremic syndrome 
Helene Werner*, Kathrin Buder*, Markus A. Landolt, Thomas J. Neuhaus, Guido F. Laube, 
Giuseppina Spartà 
 
*Equal contribution for first authorship 
Pediatr Nephrol. 2017; 32(5):869-878. 
(Werner et al 2017) 
In this paper, a cross-selectional study evaluating long-term in health-related quality of life 
(HRQoL) and psychological adjustment in children with a history of HUS is described, using a 
comprehensive single center HUS registry (Buder K 2015 and 2016). Long-term HRQoL and 
psychological adjustment, defined by behavioural problems, depressive symptoms and 
posttraumatic stress symptoms, were analyzed in 62 children with a history of HUS. HUS 
patients are at risk of late and long-term renal and extrarenal complications, such as 
neurological sequelae, visual disorders and diabetes mellitus (Schifferli A 2010). These events 
may be very stressful and impact the patients’ HRQoL and psychological adjustment, which 
are recognized as important outcome measures to evaluate the impact of a disease on an 
individual patient. While HRQoL is a multidimensional concept that focuses on the subjective 
perception of physical, emotional, social and cognitive dimensions of health, psychological 
adjustment targets the individual’s mental health by asking about the presence or absence of 
behavioural problems and/or psychological symptoms (e.g. depression). 
In this study we retrospectively collected medical data from hospital records of the children 
after a mean of 6.5 years (range 0.1-15.7) post-acute HUS episode. At study follow-up, clinical 
examination and the laboratory findings were evaluated. In addition, well-validated, 
multidimensional and standardized questionnaires with reference data, were used to assess 
HRQoL and psychological adjustment of each child. The average age of the children at the 
time of study was 9.4 years (range 1.9–16.7).  The diagnosis of HUS was classified as (1) 
typical, infection-mediated HUS, including STEC-HUS and P-HUS, or as (2) atypical HUS 
(aHUS) based on hereditary and/or acquired disorders of regulation of the alternative 
complement system. Of the 62 children enrolled in the study 42% had CKD.  
The long-term outcome measures assessed, were adapted for child age: a) in preschool 
children aged ≤ 6.5 years, (proxy report for HRQoL (TAPQOL) and CBCL for psychological 
adjustment behaviour problems); b) in school-age children, aged > 6.5 years (Self-reported 
and proxy reported for HRQoL (KIDSCREEN), and proxy-reported for psychological 
adjustment (CBCL), and CDI for Depression and PTSD Reaction Index for posttraumatic stress 
disorder (proxy reported)  
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From these evaluations among the preschool children, parents reported that children were less 
lively and energetic (HRQoL emotional dimension), but no increased behavioural problems 
were reported. Among the school-age children, self- and proxy-reported HRQoL was well 
within or even above the norm, but total behavioural problems were greater. The school-age 
children reported no increased depression scores. No child met criteria for full or partial HUS-
associated posttraumatic stress disorder. 
This study was the first to examine HRQoL in paediatric patients with a history of HUS and is 
therefore a landmark study in the field.  
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Original article 3: Health-related quality of life and mental health in parents of children 
with haemolytic uremic syndrome 
 
Kathrin Buder*, Helene Werner*, Markus A. Landolt, Thomas J. Neuhaus, Guido F. Laube, 
Giuseppina Spartà 
 
*Equal contribution for first authorship 
Pediatr Nephrol. 2016; 31(6):1035-7.  
(Buder et al 2016) 
HUS is a life-threatening disease with a mortality of 3-15% during the acute phase. Little is 
known about health-related quality of life (HRQoL) and mental health of parents having children 
with a history of HUS. We studied 63 mothers and 58 fathers of a cohort of 63 HUS-affected 
children. We retrospectively extracted medical data from the children’s hospital records. 
Parental HRQoL, mental health and posttraumatic stress disorder (PTSD) were assessed 
using standardized self-report questionnaires. The mean time since a child experienced an 
acute episode of HUS was 6.4 years. 
This paper showed that overall most parents of the study sample were doing well in terms of 
HRQoL and mental health. The HRQoL and mental health of both the mothers and fathers 
were not impaired compared to normative data.  
A small number of parents did however meet criteria for full or partial PTSD diagnosis due to 
their child’s HUS.   
This is the first study to report on long-term HRQoL and mental health in parents of HUS-
affected children. Its strengths include the use of standardized multidimensional 
questionnaires and the comparison of results with normative data.  
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Original article 4: Membranoproliferative glomerulonephritis and C3 glomerulopathy in 
children: change in treatment modality? A report of a case series 
 
Giuseppina Spartà, Ariana Gaspert, Thomas J. Neuhaus, Marcus Weitz, Nilufar Mohebbi, 
Urs Odermatt, Peter F. Zipfel, Carsten Bergmann, Guido F. Laube 
 
Clinical Kidney Journal; 2018, 1-12; doi: 10.1093/ckj/sfy006 
(Spartà et al 2018) 
In this paper the complexity of diagnosis, treatment and variability of outcome in MPGN and 
C3 glomerulopathy is shown based on a case series of seven children. MPGN and C3 
glomerulopathy are rare chronic glomerulonephritis in childhood, leading to renal failure within 
10 years in up to 50% of affected children (Cansick JC 2004; Smith RJ 2007).  In the past, 
MPGN was diagnosed and classified by renal histological features into three pathological 
subtypes. Recently, a link between dysregulation of the alternative complement pathway and 
the pathogenesis of MPGN was confirmed by findings of mutations in the genes of complement 
factor proteins in conjunction with repeatedly low serum of complement C3 (Licht C 2007). The 
histological classification has therefore been reconsidered on the basis of pathogenesis, 
separating cases into those with glomerular immune deposits staining for immunoglobulins 
and complement and those characterized by C3 deposition alone (Pickering MC 2013).  
This retrospective study evaluated the clinical presentation at disease onset and the outcome 
of three children with MPGN Type I, three with C3 glomerulonephritis (C3GN) and one with 
DDD. The children had a median age of 7.3 years at disease onset and were followed for a 
median of 9 years after diagnosis. All children were screened for the presence of genetic 
mutations of the alternative complement pathway and clinical, autoimmune data, histological 
characteristics, GFR, proteinuria, serum complement and biochemical analyses were 
assessed. Moreover, the benefit of different treatment strategies was analysed. 
The evaluation revealed a dysregulation of the complement alternative pathway and 
mutations/variations in genes of complement-factor-proteins in all children. Nephrotic 
syndrome at onset was a prognostic unfavourable factor leading to a more severe course, 
often leading rapidly to ESRD. Only 3 children had a favourable outcome, maintaining a good 
renal function. Currently there is no established treatment for MPGN and C3G in children or 
adults. Patients appear to respond differently to various therapy modalities, showing also a 
great variability independent of histological diagnosis at disease onset. 
  
Treatment with eculizumab has shown promising results in the treatment of some cases of 
MPGN and C3G (Oosterveld MJ 2015, Vivarelli M 2014). Two patients in this study 
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experienced a relevant decrease in proteinuria and stabilisation of renal function after 
treatment with eculizumab. 
Treatment regimens and cases series have been reported by others, however, there are not 
treatment guidelines. The data presented in this study are therefore an important contribution 
from the clinical- and phenotypic- point of view, adding to accumulating knowledge in the field 
of genetic and serological investigation in MPGN and C3 glomerulopathy, in order to improve 
management and to better define more tailored treatment options.  
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Discussion 
A life-threatening disease and its impact on the life of children and their parents 
When HUS occurs for the first time in a child, it always represents an incisive event in the life 
of a family, especially for the parents. The parents mostly report that their child had been 
healthy before onset of the disease. Therefore, the family is confronted with a sudden, life-
threatening disease. The parents are informed that their child can die of HUS and its 
complications. Because of the severity of the disease, in most cases the child is hospitalized 
on an intensive care unit. This unforeseeable event can be compared with a sudden trauma 
(e.g. accident). Often the parents are shocked by the diagnosis, hence, the days following the 
event are crucial. Frequently, the first question of the parents is: “Why did this happen?”, 
followed by the questions “How can the disease be treated?” and “What are the 
consequences?” Therefore, doctors and researchers have the task to try to get to the bottom 
of these questions. 
HUS is a multi-organ disease, and acute renal failure is frequently the first event. About 90% 
of HUS cases in childhood are infection-induced i.e. they are typical HUS forms, mainly 
associated with infections caused by Shiga-toxin producing bacteria, usually 
enterohaemorrhagic Escherichia coli (STEC-HUS), but in some regions Shigella dysenteriae 
type 1 is also found. Gastroenteritis may therefore often precede HUS. In addition, infections 
with Streptococcus pneumoniae (P-HUS) and other bacterial and viral agents can trigger HUS 
(Noris M 2009; Loirat 2012). Only 5-10% of the cases are defined as atypical HUS (aHUS) 
based on various hereditary and/or acquired disorders of the alternative complement pathway 
regulation. Extrarenal manifestations are frequent in all forms of HUS and may affect the 
central nervous system (CNS), gastrointestinal tract, heart, eyes, lungs and skin. CNS 
involvement represents a major complication associated with increased mortality and risk for 
neurological sequelae (Siegler RL 1994). 
The term HUS encompasses a heterogeneous group of disorders, including STEC-HUS and 
aHUS. In the latter genetic or acquired dysregulation of the complement alternative pathway 
is detected in 40-60% of patients. Cobalamin C and DGKE deficiency are two rare metabolic 
genetic forms of HUS. However, approximately 30% of aHUS arises through unknown 
mechanisms. Currently it is still debated whether secondary HUS (figure 2) should or should 
not be included in the spectrum of aHUS. Most classifications exclude TMAs or HUS secondary 
to underlying diseases, labelled as secondary TMAs or secondary HUS, from the spectrum of 
aHUS. Classifications are still in progress, nevertheless the identification of the mechanisms 
underlying TMAs has become central in defining HUS (Fakhouri F 2017). 
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In recent years the majority of follow-up studies in patients with HUS have focused on mortality 
and renal outcome after a HUS episode (Fremeaux-Bacchi V 2013). In children the results 
revealed that about 30% of survivors after typical HUS demonstrate long-term renal sequelae 
(e.g. proteinuria, arterial hypertension, impaired renal function). The mortality rate is higher in 
atypical HUS (aHUS) and higher in children than in adults (6.7% vs 0.8% at 1 year). However, 
progression to ESRD after a first episode of aHUS is more frequent in adults than children 
(46% vs 16%) and a higher severity of acute Illness is strongly associated with a worse long-
term prognosis. There is evidence that patients with CNS symptoms (coma seizures, or stroke) 
and those who need dialysis may have a higher mortality or risk of permanent ESRD at follow 
up (Garg AX 2003).  
However, data reporting on neurodevelopmental outcome in children after HUS are scarce. 
The study presented in article 1 was therefore performed to determine the influence of CNS 
involvement during acute HUS disease on the long-term neurodevelopmental outcome. The 
study focused on the long-term intellectual and neuromotor performance in children after HUS, 
including all HUS forms based on the hypothesis that all children with HUS may have a higher 
risk for adverse neurodevelopmental outcome. The study showed that all patients had an 
overall favorable neurodevelopmental outcome after a history of HUS, with a normal full-scale 
IQ. In addition the intellectual performance was not affected by CNS involvement during an 
acute HUS episode. However, socioeconomic status was positively correlated with full-scale 
IQ, which is consistent with findings in healthy controls (Largo RH 1989). One-third of the 
children presented with neurological symptoms during the acute episode of HUS, particularly 
with seizures and altered consciousness. There are no evidence-based guidelines on the 
treatment of CNS complications in HUS. Plasmapheresis may benefit some children with 
severe CNS complications. Recently, Pape et al, (2015) showed, that early use of eculizumab 
in children with typical HUS and CNS involvement may improve neurological outcomes. 
However, in severe HUS cases with rapid progression and multiple organ involvement, late 
treatment with eculizumab has shown less benefit. It is hypothesized therefore that 
prophylactic therapy with eculizumab, before the development of neurological symptoms, 
could be advantageous. Recent experimental data suggest involvement of the complement 
pathway also in typical HUS potentially opening new treatment avenues for typical HUS. 
In article 1, neurocognitive outcomes were favorable in most children after HUS, however 
patients who developed ESRD showed a significantly poorer outcome after HUS compared to 
patients without ESRD. Overall, neuromotor performance was more impaired than IQ 
particularly fine and gross motor functioning, static balance and movement quality were 
impaired. Interestingly, motor performance did not differ between children with and without 
CNS impairment during acute HUS episode. However, 15-38% of the patients had a motor 
performance below 10% percentile. This poorer motor performance is clinically significant as 
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children who perform below the 10th percentile often have difficulties participating in activities 
of daily life and demonstrate poorer hand writing skills and slower speed. The pathophysiologic 
mechanisms leading to impaired neuromotor outcome after HUS remain to be elucidated. In 
addition to cerebral thrombotic microangiopathy and uremia, other factors, such as long 
hospital stay, more parental protectiveness and less experience may contribute to adverse 
neuromotor performance as described in other cohorts of paediatric patients with various 
diseases (Schaefer C 2013). 
It is therefore plausible that an HUS event may have an important impact on the quality of life 
of children and their parents, as shown in article 2 and article 3. HUS patients are at risk for 
late and long-term renal and extra-renal complications. This situation may be very stressful for 
patients and their parents. We hypothesized a negative impact of the disease on patients’ and 
parents’ health-related quality of life (HRQoL). The results indicate that the patients’ HRQoL 
was comparable to normative data. However, a few parents suffered from full or partial 
posttraumatic stress disorders (PTSD) due to their child’s HUS. 
Overall HRQoL of the children with a history of HUS was not impaired, as shown in article 2. 
As there are no prior studies on this topic, no comparison with the literature was possible. In 
article 2, the parents of pre-school children rated their child’s HRQoL as similar - or even 
better- than a normal control group. This may be explained by the possibility that they rated 
their child’s current HRQoL in comparison to that of when their child was sick. These results 
are in contrast to those of other studies indicating lower HRQoL in paediatric patients with 
chronic kidney disease (CKD) compared to healthy controls. Indeed in our study, the rate of 
CKD was 42%, therefore lower than in other studies, which may explain the better HRQoL. 
However, our study is in line with Askenazi et al (Kidney Int 2006) who observed no difference 
in long-term HRQoL in children 3-5 years of age after acute renal failure of various causes. 
Thus, in our study, children with a history of HUS, even when severe, appear to recover quite 
well over the long-term, and the patient’s acute medical characteristics (e.g. longer length of 
stay in ICU in severe case) have a minor impact on long-term HRQoL. Furthermore, the data 
revealed, that neither medical characteristics during an acute episode nor the presence of CKD 
were significantly associated with impaired HRQoL reported by the parents in pre-school 
children. In contrast, a lower self-reported HRQoL was observed among school-age children 
in association with the presence of CKD. Regarding the psychological adjustment, the parents 
reported increased total behavioral problems among school-age children. This is in contrast to 
other studies which found no clinically significant behavioural problems in children with a 
history of HUS (Schlieper A 1999).  These difference may be explained by the longer period 
since acute HUS in the CKD patients and the high number of children affected by CKD. Thus, 
school-age children with a history of HUS may be at risk of poorer psychological adjustment. 
A longer stay in ICU as well as longer periods of dialysis and hospital stay were significantly 
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associated with more parent-reported total behavioural problems. Thus, these medical 
characteristics can be seen as risk factors for long-term psychological maladjustment in 
children with a history of HUS. None of the school-age children in our cohort perceived HUS 
as a traumatic event or met criteria for full or partial PTSD. This in contrast to the parents, 
some of whom met the criteria for full or partial PTSD (Buder K 2016) as revealed in article 3. 
Therefore, knowledge of parents’ impairment in mental health and quality of life are also 
important, as it may impact the child’s adjustment to the disease. Thus, it has been shown that 
parents with increased problems may be too absorbed in regulating their own feelings to be 
able to provide sensitive support for their child. Findings in article 3 showed that HRQoL and 
mental health were not impaired in the mothers and fathers compared to normative data, 
although a full, HUS-related PTSD was diagnosed in two fathers but no mothers. Overall, 
parental HRQoL was comparable to or even greater than the population norm, which is 
consistent with findings from a number of previously published studies on HRQoL in parents 
of children with other life-threatening or chronic diseases (e.g. meningococcal septic shock, 
Kawasaki syndrome or juvenile polyarthritis). Interestingly, this differs from findings in parents 
of children with ESRD, where HRQoL was lower than that of parents of healthy controls 
(Hatzmann J 2008). One possible explanation for the findings in article 3 is the small number 
of children with ESRD or advanced CKD. Another possible explanation for the positive results 
of our study may be that the parents of HUS-affected children rate their own physical health 
as better than the norms because they rate their health in comparison to that of their sick child. 
Also, a shorter time since an acute episode of HUS was a significant predictor of lower 
maternal HRQoL, which is consistent with findings in mothers of children having other chronic 
disease (e.g. heart disease). No significant association between HUS–related or 
sociodemographic characteristics and parental mental health was observed. 
TMA and HUS as a link to other glomerulopathies  
Based on recent advances in knowledge regarding the clinical and pathophysiological aspects 
of TMA, especially in HUS, interest has increased in glomerulopathies and other renal diseases 
where complement involvement was suspected e.g. because of low complement C3, 
haemolysis or thrombocytopenia. The finding of one or more common denominators in TMA 
with different diseases has led to growing research in the field of complement diseases.  
As described in article 4, in membranoproliferative glomerulonephritis (MPGN) and C3-
glomerulopathy (C3G), the hereditary and acquired complement defects are similar, although 
subtly different to those seen in complement-mediated aHUS, and it is perhaps not surprising 
that concurrent and sequential manifestation of C3G and TMA have been reported (Manenti L 
2013; Cooper M 2004). Mutations in CFH are observed in both complement-mediated aHUS 
and C3G; the reason for this genetic pleiotropy is not fully understood, but the location of the 
28 
 
mutation within the gene may be important. In aHUS, the majority of the mutations are located 
at the C-terminal of FH, which binds to C3b and glycosaminoglycans on host cells to mediate 
cell surface protection, whereas in C3G, mutations are more often located at the N-terminal of 
FH, which mediates complement regulation in the fluid phase. Studies from different small case 
series revealed that clinical presentation and the measurement of plasma C3, C3d and sC5b-
9 do not allow differentiation between C3G and MPGN. 
We observed similar findings in our case series of 7 children described in article 4. Genetic 
analysis revealed a dysregulation of the alternative complement pathway and 
mutations/variation in genes of complement factors proteins in all 7 children with MPGN, C3 
glomerulonephritis and dense deposit disease (DDD). Three patients had a favorable outcome: 
two patients with MPGN I and one with C3GN, the latter without any genetic variation in CFHR 
proteins. Five of seven children had a heterozygous mutation/deletion or variation in CFHR 
proteins 1, 2, 3 or 5. Genetic alterations, including variations or polymorphisms could at least 
in part explain the different outcomes and responses to various treatment modalities (e.g. 
renin-aldosteron-angiotensin-receptor-blockers, immunosuppressive drugs, eculizumab, 
plasmapheresis). There is currently no established treatment for these diseases. Recently, 
treatment with eculizumab, a monoclonal antibody binding to C5 of the alternative pathway, 
has shown promising results in the treatment of some cases of MPGN and C3G. Two patients 
in our series, one with C3GN and one with MPGN I, exhibited a significant decrease in 
proteinuria in their native kidney after eculizumab, but elevated activity of the alternative 
pathway persisted. Consistent with observations of other authors treating MPGN, this finding 
suggests that eculizumab is not completely effective in inhibiting sC5b-9 activity in C3G, and 
it is suspected that sC5b-9 alone may not reflect disease activity. 
Secondary atypical HUS has been described in association with infective agents, including 
HIV. Other causes identified for secondary HUS include connective tissues diseases, 
pregnancy and post-transplantation associated TMA. Several drugs have also been reported 
to induce TMA. TMA can also occur in association with IgA nephropathy, ANCA-associated 
vasculitis, membranous nephropathy, FSGS, although it may be a histopathological finding 
without biochemical or clinical manifestation (Brocklebank V 2017). 
In the view of the heterogeneity in pathophysiological, clinical and genetic presentation of 
TMA/HUS-associated diseases, new treatment therapies are under development and will 
hopefully become available in the next years in order to optimize treatment for these complex 
diseases. 
Conclusions 
The main goal of the studies reported here was to improve understanding of the management 
and long-term outcome in children with HUS. Children and adolescents with HUS have a 
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normal intellectual outcome, but a significant impairment in motor function. Neurological 
complications during the acute episode of HUS were not associated with a poorer 
neurodevelopmental outcome. Therefore, long-term observation of all children after HUS is 
advisable for the early detection of neurodevelopmental deficits. Healthcare providers should 
also be especially alert for any signs of behavioural problems in school-age children with a 
history of HUS and for a lower HRQoL in the preschool children. Early detection of any of these 
abnormalities could permit interventions that may minimize the long-term impact. Similarly, 
healthcare providers should pay special attention to parents’ reports of PTSD symptoms during 
the clinical follow-up of a child with HUS. Although the prevalence of HUS-related PTSD seems 
to be small, even partial PTSD might lead to functional impairment and some parents would 
benefit from psychological support. Therefore, knowledge of the impairments in parental HUS-
related PTSD might help to identify those aspects of the clinical experience which most strongly 
affect the parents to permit better parental support during the acute illness, and, if necessary, 
to enable these parents to be monitored closely and to get access to psychological support. 
Methodological differences and the small number of patients in single-center studies make it 
difficult to compare findings in the literature. Therefore, it would be advisable to perform 
multicenter-studies in order to optimize generalizability of the results. Based on previous 
studies, investigation of HRQoL and mental health in other caregivers (e.g. siblings, 
grandparents) may be of importance in families of children after an HUS-event. 
Concerning the pathophysiology of TMA and HUS, many questions remain still open and need 
to be clarified. There is evidence of complement activation (e.g. low C3 plasma levels and 
tissue staining) in many TMAs, but whether this is a primary event, a disease modifier, or a 
bystander phenomenon has not yet been definitively established. In addition, the relative roles 
of effector molecules (e.g.C5a, C5b-9) of the alternative pathway in causing disease also 
remains to be established. 
In a clinical setting, it is relevant to consider counseling of family members and to perform 
genetic tests, which are cost-effective and easily accessible, in order to provide early and more 
rapidly diagnosis of TMA-associated diseases. This approach would support genetic screening 
over a larger area and increase knowledge concerning TMA-associated diseases as well as 
permit appropriate tailoring of treatment-guidelines. 
Our results strongly support the need for a formal transition from paediatric to adult nephrology 
care especially after HUS, as renal (and extrarenal) long-term complications after HUS in 
childhood (e.g. proteinuria, hypertension, renal insufficiency) can occur late in adult life. 
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Abstract
Background To investigate the long-term neurodevelopmental
outcome in children after hemolytic uremic syndrome (HUS)
and to compare outcome dependent on central nervous system
(CNS) involvement during HUS.
Methods A single-center retrospective cohort of 47 children
was examined at a median age of 10.6 (range 6–16.9) years
and a median follow-up of 7.8 (range 0.4–15.3) years after
having had HUS. Intellectual performance was assessed with
the German version of the Wechsler Intelligence Scale 4th
version and neuromotor performance with the Zurich
Neuromotor Assessment (ZNA). The occurrence of neurolog-
ical symptoms during the acute phase of HUS was evaluated
retrospectively.
Results Mean IQ of the whole study population fell within the
normal range (median full scale IQ 104, range 54–127).
Neuromotor performance was significantly poorer in the do-
mains “adaptive fine,” “gross motor,” “static balance” (all
p<0.05) and “associated movements” (p<0.001); only the
“pure motor” domain was within the normal reference range.
Neurological findings occurred in 16/47 patients (34 %) dur-
ing acute HUS. Neurodevelopmental outcome was not signif-
icantly different between children with or without CNS
involvement.
Conclusions Our follow-up of children after HUS showed a
favorable cognitive outcome. However, neuromotor outcome
was impaired in all study participants. Neurological impair-
ment during acute HUS was not predictive of outcome.
Keywords Intellectual . Motor . Neurocognitive outcome .
Central nervous system involvement . Hemolytic uremic
syndrome
Introduction
Hemolytic uremic syndrome (HUS) is a multi-organ and life-
threatening disease characterized by hemolytic anemia,
thrombocytopenia and acute renal injury. HUS is also one of
the most frequent causes of acute renal failure in childhood [1]
and may result in long-term renal and extrarenal sequelae
[2–5].
About 90 % of HUS cases in childhood are infection-
induced, i.e. they are typical HUS forms, mainly mediated
by infections caused by Shiga toxin-producing bacteria, usu-
ally enterohemorrhagic Escherichia coli (STEC-HUS) but in
some regions Shigella dysenteriae type 1. In addition, infec-
tions with Streptococcus pneumoniae (P-HUS) and other bac-
terial and viral agents can trigger HUS [6, 7]. Only 5–10 % of
cases are defined as atypical HUS (aHUS) based on various
hereditary and/or acquired disorders of the alternative com-
plement pathway regulation [6–8]. Renal replacement therapy
at disease onset is required in up to 65 % of STEC-HUS
patients [9], 84 % of those with P-HUS [10] and 59 % of
aHUS patients [5].
Extrarenal manifestations are frequent in all HUS forms,
including STEC-HUS [11, 12], P-HUS [13, 14] and aHUS [5,
15], and may affect the central nervous system (CNS), gastro-
intestinal tract, heart, eyes, lungs, parotid glands and skin.
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CNS involvement represents a major complication that is
associated with increased mortality [2, 11] and risk for neuro-
logical sequelae [16].
Studies reporting on neurodevelopmental outcome in chil-
dren after HUS are scarce, and the results suggest a normal
neurocognitive outcome [17–19]. However, a trend towards
impaired full-scale and verbal comprehension IQ in these
children has also been described [17]. Data on neuromotor
outcome are limited to information on impaired fine motor
skills in children with a history of HUS and severe CNS
involvement [18].
In the study reported here, we focused on the long-term
intellectual and neuromotor performance in a single-center
cohort of children after HUS, including typical and atypical
HUS forms. The hypothesis was that all children with HUS
may have a higher risk for adverse neurodevelopmental out-
come. Furthermore, the study was performed to determine the
influence of CNS involvement during acute HUS disease on
the long-term neurodevelopmental outcome.
Methods
Patients
The study cohort consisted of 47 children (22 males, 25
females; median age 10.6 years, age range 6–16.9 years) with
a history of both typical infection-induced HUS and atypical
HUS. The neurodevelopmental testing was part of a compre-
hensive single-center study on long-term renal outcome, psy-
chological adjustment and quality of life in HUS patients. The
study was approved by the Cantonal Ethics Committee Zurich
and registered at ClinicalTrials.gov (NCT 01666548). Written
informed consent was obtained by the parents and by the
adolescents themselves if they were ≥15 years. Inclusion
criteria for neurocognitive and neuromotor assessment were:
(1) previous diagnosis of HUS and (2) age between 6 years
and 16 years 11 months during the study period between
February 2012 and February 2013.
HUSwas defined as non-immunological hemolytic anemia
(hemoglobin<100 g/l), thrombocytopenia (thrombocytes
<150.000/μl) and features of acute renal injury (plasma creat-
inine elevation above the age-related norm range; proteinuria,
hematuria or renal ultrasound abnormalities). Two of the
enrolled patients—one with STEC-HUS requiring dialysis
and one with recurrent aHUS due to complement factor H
mutation—did not meet the criteria for thrombocytopenia.
The diagnosis of HUS in all patients was confirmed by pedi-
atric nephrologists. Based on the different approaches used in
published studies to classify HUS [20–22] we categorized the
disease as (1) typical, infection-induced HUS, including
STEC-HUS and P-HUS, and (2) aHUS based on currently
proposed HUS nomenclature [21].
The age criterion of 6–16 years was used to study long-
term neurocognitive outcome using one intellectual test,
namely, the German version of the Wechsler Intelligence
Scale 4th version [23].
Participants were recruited from a sample of 129 pa-
tients treated for HUS at the Pediatric Nephrology Unit of
Zurich University Children’s Hospital between April 1995
and February 2013. Seven patients died during an acute
episode of HUS, five patients were lost to follow-up and
42 patients did not fulfil the age criterion (26 were aged
<6 years and 16 were aged≥17 years). Thus, 75 patients
were eligible for the study. Twenty-six parents or children
refused to participate; two additional patients were ex-
cluded due to a pre-existing neurodevelopmental impair-
ment resulting from trisomy 21 in one and an unclassified
syndrome in another. The final study cohort included 47
(63 %) of the children originally eligible for entry.
Demographic and clinical characteristics did not differ
significantly between enrolled patients and those not en-
rolled in terms of sex, HUS form, socioeconomic status,
age at diagnosis of HUS, frequency of neurological com-
plications during the acute phase of HUS, occurrence of
anuria, need for dialysis during the acute phase of HUS,
length of hospital stay, estimated glomerular filtration rate
(eGFR) at time of discharge, need of dialysis at time of
discharge and development of end-stage renal disease
(ESRD).
The clinical and demographic data needed to evaluate
potential risk factors were extracted from patients’ records
and analyzed retrospectively. Values for the following
parameters were obtained from the medical records: sex,
age at disease onset, renal function, anuria defined as
urine output<0.2 ml/kg per hour, requirement of dialysis
and CNS involvement during the acute episode of HUS.
CNS involvement was defined as presence of neurological
findings including seizures, altered consciousness, ataxia,
muscle tone abnormalities, hemiplegic symptoms, dysar-
thria, visual disorders, movement disorders and vestibular
symptoms. Since conditions such as anemia or dehydra-
tion may affect mental status, CNS involvement was only
considered if the clinical symptoms were severe and not
attributable to an underlying non-cerebral medical condi-
tion. None of the studied children had a neurological
disease prior to HUS.
Other comorbidities and ESRD with renal replacement
therapy at follow-up were also recorded. Renal function was
evaluated by eGFR, expressed in millimeters per minute per
1.73 m2, according to the Schwartz formula using the local
factor k of 40 for all children and by the plasma creatinine
concentration (in μmol/l) [24]. Information on additional po-
tential neurological risk factors and interventions performed
since HUS was retrieved from parental interviews at the time
of neurodevelopmental assessment.
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Neurodevelopmental outcome assessment
The neurodevelopmental outcome assessment included as
assessment of intellectual and neuromotor performance and
a standardized neurological examination [25]; both were per-
formed at the Child Development Center of Zurich University
Children’s Hospital by one experienced developmental pedi-
atrician. Socioeconomic status was estimated based on mater-
nal education level and paternal occupation using an educa-
tion scale ranging from 2 to 12, with 2 being the lowest and 12
the highest education score [26].
Intellectual performance
Of the 47 participants, 46 were assessed using with the
German version of theWechsler Intelligence Scale 4th version
[23]. This test provides IQ subscales for verbal comprehen-
sion, perceptual reasoning, working memory and processing
speed, which together form the full-scale IQ. One 9-year-old
patient with P-HUS associated with meningitis and serious
neurological complications was not able to perform the
Wechsler Intelligence Scale 4th version and was examined
using the German version of the Wechsler Preschool and
Primary Scale of Intelligence 3rd version [27].
Neuromotor performance
Neuromotor performance was examined with the Zurich
Neuromotor Assessment (ZNA), a standardized, videotaped
test for children aged 5 to 18 years which is used to investigate
specific motor skills based on timed performances and move-
ment quality [28, 29]. The ZNA contains five block compo-
nents including: (1) pure motor domain, (2) adaptive fine
motor domain, (3) adaptive gross motor domain, (4) static
balance and (5) associated movements. The results are
expressed as z-scores, i.e. the standard score of the reference
population based on age and sex.
Statistical analysis
Statistical analysis was performed with SPSS for Windows
version 20.0 and 22.0 (IBM Corp,, New York, NY).
Differences between participants’ data and normative data
were calculated using the univariate t test, and differences
between subgroups were assessed using the Mann–Whitney
U test for continuous variables and Fisher’s exact test for
categorical variables. Multivariate linear regression was con-
ducted to evaluate the association between risk factors and
full-scale IQ scores. Variables included in the regression mod-
el were socioeconomic status, duration of hospital stay, CNS
involvement and eGFR at time of discharge. Two children
with very low full-scale IQ scores (54 and 62) were excluded
for the multiple regression analysis in order to complywith the
requirements of a normal distribution in the study sample. A p
value of<0.05 was considered to be statistically significant.
Results
Sample description
Forty-seven patients (22 boys and 25 girls; median age
10.6 years, range 6–16.9 years) with a history of STEC–HUS
(n=38), P-HUS (n=6) and aHUS (n=3) and a median follow-
up after HUS of 7.8 (range 0.4–15.3) years participated in this
study (for detailed information on each participant, see Table 1).
Of the 38 STEC-HUS patients, 24 tested positive for Shiga
toxin. Genetic analysis of the three aHUS patients revealed one
or more mutations of complement-related factors. The median
age at onset of HUS was 1.8 (range 0.3–14.4) years. Thirty-
three children (70 %) required acute renal replacement therapy
combined with either peritoneal dialysis (n = 24 patients),
hemofiltration or hemodialysis (n = 6) or a combination of both
treatment modalities (n = 3). At time of discharge the median
eGFR was 54 (range 13–178) ml/min per 1.73 m2. Forty-one
(87 %) patients had an impaired eGFR defined as<90 ml/min
per 1.73 m2. One patient was on dialysis when discharged and
remained on dialysis for 127 days, subsequently progressing to
ESRD. Five patients developed ESRD, of whom four
underwent renal transplantation (RTPL) (Table 1).
The median eGFR at neurodevelopmental testing—exclud-
ing the four children who underwent RTPL—was 113 (range
12–178) ml/min per 1.73m2; ten of these children had impaired
renal function with an eGFR of<90 (range 12–88) ml/min per
1.73 m2. Two of the four patients undergoing RTPL had good
renal graft function defined as an eGFR of>60 (respectively 92
and 163) ml/min per 1.73 m2, while the remaining two children
showed impaired graft function (47 and 54ml/min per 1.73 m2,
respectively). The children with CNS involvement has a sig-
nificantly lower median eGFR at both discharge and follow-up
(46 and 89ml/min per 1.73m2, respectively; p=0.014) than the
children without CNS involvement (83 and 126 ml/min per
1.73 m2, respectively; p=0.004) (Table 2).
CNS involvement during acute episode of HUS
Sixteen children (34 %) presented with CNS involvement
during the acute episode of HUS with a broad spectrum of
neurological symptoms, consisting predominantly of seizures
(12/16) or altered consciousness (7/16) (Table 3).
In the STEC-HUS group neurological symptoms were
observed in 12 of 38 patients. Two children received treatment
with plasmapheresis due to severe neurological complications
(Table 1). Four of the six P-HUS patients presented with
neurological symptoms, including two with pneumococcal
meningitis. None of the patients with aHUS manifested CNS
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involvement, but one was resuscitated due to respiratory fail-
ure following RTPL.
Neuroimaging studies were performed in 12 of 16 patients
with CNS involvement (cerebral computed tomography in 7,
cerebral magnetic resonance imaging in 5 and both investiga-
tions in 5 children), revealing cerebral abnormalities in five
patients: two with cerebral infarctions (both STEC-HUS), two
with meningitis-associated complications and one child with
leukoencephalopathy (P-HUS) (Table 1).
Comparison of clinical and demographic characteristics
between participants without and with CNS involvement dur-
ing the acute episode of HUS showed that anuria (p=0.006),
longer duration of hospital stay (p=0.03) and impaired eGFR,
both at discharge (p=0.01) and at time of neurodevelopmental
testing (p=0.004), were significantly more common in pa-
tients with CNS impairment (Table 2).
Additional comorbidities, not HUS related and potentially
leading to neurodevelopmental impairment, were present in
four children, with one child each having status after viral
meningitis and resuscitation for pulmonary edema after
RTPL, resuscitation associated with an anesthetic accident,
prematurity and attention deficit hyperactivity disorder treated
with methylphenidate, respectively. Two additional children
with P-HUS developed severe cerebral complications
(Table 1): subdural empyema and hydrocephalus, respectively.
Intellectual performance
The median full-scale IQ of the study cohort was normal with
a value of 104 {54–127 points; comparison to norm of 100
[±15=1 standard deviation (SD)]: p=0.39}. All subscales
were in the normal range: verbal comprehension [102 (range
Table 2 Demographic and clinical characteristics of the 47 hemolytic uremic syndrome (HUS) patients enrolled in the study
Demographic and clinical characteristics CNS involvement during acute episode
of HUS (n=16)
No CNS involvement during acute
episode of HUS (n=31)
p value
General data
Sex: male/female (n) 6/10 16/15 0.54
HUS-classification (n)
STEC-HUS 12 26
P-HUS 4 2
aHUS 0 3
Socioeconomic status score 8 (7–12) 8 (2–12) 0.38
Acute episode of HUS
Age (years) 1.3 (0.3–14.4) 2.2 (0.4–13.3) 0.24
Anuria (n) 14 14 0.006*
Duration of anuria (days) 8 (1–46) 9 (2–20) 0.58
Dialysis (n) 14 19 0.09
Duration of dialysis (days) 13 (5–79) 11 (3–23) 0.18
Mode of dialysis
Peritoneal dialysis (n) 9 14
Hemofiltration/hemodialysis (n) 4 2
Combination of peritoneal dialysis and
hemofiltration/hemodialysis (n)
1 3
Duration of hospital stay (days) 26 (10–97) 16 (5–54) 0.030*
eGFR at discharge (ml/min per 1.73 m2) 46 (13–125) 83 (14–178) 0.014*
Dialysis at discharge (n) 1 0 0.34
Follow–up
Age (years) 11.1 (6.3–16.3) 10.4 (6.0–16.9) 0.50
Time interval HUS to follow-up (years) 9.1 (0.6–15.3) 7.2 (0.4–15.1) 0.27
Development of ESRD (n) 2 3 1.00
Duration of dialysis in total (acute and chronic) (days) 13 (5–218) 12 (3–1560) 0.65
Status after RTPL (n) n 1 3 1.00
eGFR at neurodevelopmental examination (ml/min per 1.73 m2) 89 (12–141) 126 (47–178) 0.004*
*Significant difference at p< 0.05
Results are presented as the median with the range in parenthesis
CNS, Central nervous system; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; RTPL, renal transplant; STEC-HUS,
Escherichia coli hemolytic uremic syndrome; P-HUS, Streptococcus pneumoniae hemolytic uremic syndrome; aHUS, atypical hemolytic uremic
syndrome
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69–130); p–0.57], working memory [102 (54–144); p=0.52],
processing speed [100 (65–129); p=0.69] and perceptual rea-
soning [108 (61–129); p–0.03].
Six children (13 %) showed a full-scale IQ of<85 (−1 SD).
Two of these two patients had a full-scale IQ of<70 (−2 SD)—
one with P-HUS and pneumococcal meningitis and multiple
complications requiring ventriculoperitoneal shunt and co-
chlear implant and the second with a past history of resusci-
tation episode, aHUS and ESRD in infancy (Table 1).
Children with a history of ESRD showed a poorer
neurocognitive outcome than children without ESRD in terms
of verbal comprehension [88 (range 69–95) vs. 105 (79–130);
p=0.004], working memory [87 (54–102) vs. 102 (74–144);
p=0.008] and full-scale IQ [84 (54–103) vs. 105 (62–127);
p=0.010].
There were no significant differences between the 16 indi-
viduals with and the 31 individuals without CNS involvement
during the acute phase of HUS (Table 4). Socioeconomic status
did not differ between these two groups (Table 2). Furthermore,
the exclusion of patients with neurodevelopmental comorbidi-
ties (n=6) and those with development of ESRD (n=5) did not
significantly alter the results of the intellectual outcome.
Neuromotor performance
Forty-seven children (22 boys, 25 girls) performed the ZNA.
Except for the pure motor domain, all other domains of the
neuromotor performance were significantly impaired com-
pared to the normal controls (Table 5). Between 15 and
38% of the children performed poorer than the 10th percentile
within the five ZNA domains (Table 5).
Table 3 Neurological symptoms of the 16 patients enrolled in the study
with CNS involvement during acute HUS
Neurological symptoms Frequency
Seizures 12/16
Isolated seizures 5/16
Altered consciousness 7/16
Isolated altered consciousness 2/16
Ataxia 4/16
Muscle tone abnormality 2/16
Hemiplegic symptoms 2/16
Dysarthria 1/16
Visual disorders 1/16
Movement disorders 2/16
Vestibular symptoms 1/16
>1 neurological symptoms 8/16
Number of neurological symptoms
1 8/16
2 5/16
3 0/16
4 1/16
5 2/16
Results are presented as the number of patients
CNS, Central nervous system; HUS, hemolytic uremic syndrome
Table 4 Intellectual performancea of the 16 children with and 31 children without CNS involvement during the acute episode of HUS (n=47)
Full-scale and subscale IQ CNS involvement during acute
episode of HUS (n=16) b
No CNS involvement during acute
episode of HUS (n=31)
p-value
Full-scale IQ 105 (62–127)b 104 (54–127) 0.62
Verbal comprehension index 99 (81–124) 103 (69–130) 0.49
Similarities 11 (6–14) 12 (4–17) 0.51
Vocabulary 10 (5–15) 10 (3–14) 0.76
Comprehension 9 (6–16) 10 (7–19) 0.31
Perceptional reasoning index 108 (81–117) 108 (61–129) 0.81
Block design 12 (5–16)b 12 (5–18) 0.74
Picture concepts 10 (6–14) 10 (2–13) 0.84
Matrix reasoning 11 (8–14) 11 (2–18) 0.90
Working memory index 102 (56–135) 102 (54–144) 0.98
Digit span 10 (3–16) 10 (3–16) 0.78
Arithmetic 10 (2–17) 11 (1–19) 0.60
Processing speed index 96 (71–129)b 103 (65–129) 0.29
Coding 9 (4–14)b 10 (4–14) 0.40
Symbol search 10 (5–16)b 12 (3–16) 0.40
Results are presented as the median IQ score, with the range in parenthesis
CNS, Central nervous system; HUS, hemolytic uremic syndrome
a Intellectual performance was assessed using the Wechsler Intelligence Scale 4th version
b One patient (Table 1, patient no. 44) was not able to perform theWechsler Intelligence Scale 4th version except the subtests “Block design”, “Coding”
and “Symbol Search.. His results are only included in the subtests, processing speed index and full scale IQ
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When participants with additional neurodevelopmental co-
morbidities were excluded, the neurodevelopmental outcome
compared to normal controls was still impaired except for the
pure motor and the adaptive fine motor domain (p>0.07).
Participants with a history of ESRD (n=5) had significantly
poorer results in the domain static balance than those without
ESRD [−1.9 (range −3.0 to −0.7) vs. −0.2 (−3.0 to 1.7); p=
0.003].
Motor therapies (including psychomotor, physical and
ergotherapy) were reported for nine children (19 %). There
were no significant differences between children with and
without CNS involvement in terms of frequency of motor
therapies (6/31 vs. 3/16, respectively; p=0.64).
Neurodevelopmental outcome in children with STEC-HUS
Table 6 presents the developmental outcome for children with
only STEC-HUS—which was the commonest HUS form pres-
ent in the study cohort (n=38). Compared to normal controls,
children with STEC-HUS showed a favorable intellectual
outcome. In contrast, neuromotor outcome was impaired
in the ZNA domains “adaptive gross motor” and “associated
movements”. In these domains, 34 % and 39 % respectively
performed poorer than the 10th percentile (Table 6).
Prognostic factors
Potential risk factors for poorer IQ were evaluated in a multi-
variate linear regression analysis . Socioeconomic status (ß=
0.474, p=0.001) was the only factor associated with the full-
scale IQ whereas CNS involvement (ß=−0.074, p=0.62),
duration of hospital stay (ß=−0.257, p=0.08) and eGFR at
time of discharge (ß=−0.117, p=0.41) were not.
Discussion
The majority of follow-up studies of children with HUS have
focused on renal outcome after HUS episode [2–5, 9, 15].
Data on neurodevelopmental outcome, however, are scarce,
with only few published studies of various designs and case
series available [18, 30], and little information on long-term
Table 5 Motor performancea data of all patients (n=47) and of the 16 children with and 31 children without central nervous system (CNS) involvement
during the acute episode of hemolytic uremic syndrome (HUS)
Zurich Neuromotor
Assessment domains
All patients CNS involvement during
acute episode of HUS (n=16)
No CNS involvement during acute
episode of HUS (n=31)
p valued
z-score <P10b p valuec
Timed performances
Pure motor 0.10 (−5.5 to 4.6) 15 % (7/47) 0.73 0.25 (−5.5 to 1.7) 0.10 (−2.4 to 4.6) 0.65
Adaptive fine motor −0.30 (−3.6 to 3.5) 28 % (13/46) 0.042* −0.23 (−2.7 to 1.2) −0.30 (−3.6 to 3.5) 0.72
Adaptive gross motor −1.00 (−7.5 to 2.5) 36 % (16/45) 0.003* −1.30 (−7.5 to 2.2) −1.00 (−3.4 to 2.5) 0.19
Static balance −0.25 (−3.0 to 1.7) 17 % (8/46) 0.007* −0.20 (−3.0 to 0.6) −0.30 (−3.0 to 1.7) 0.84
Associated movements −1.10 (−3.2 to 2.0) 38 % (18/47) <0.001* −1.25 (−3.2 to 0.2) −0.90 (−2.3 to 2.0) 0.10
*Significant difference at p< 0.05
Results are presented as the median z-score with the range in parenthesis
aMotor performance was assessed using the Zurich Neuromotor Assessment (ZNA)
b <P10 indicates the proportion of patients presenting with z-scores of<−1.282 (i.e. results<10th percentile)
c p value calculated for z-score difference to norm
d p value calculated for z-score difference between patients with and without CNS involvement
Table 6 Neurodevelopmental outcome of 38 children with STEC-HUS
Assessment tool Neurodevelopmental outcome
Score p value <P10a
Wechsler Intelligence Scale
4th version
Full-scale IQ 104.5 (82–127) 0.003*
Verbal comprehension index 104 (79–124) 0.10
Perceptional reasoning index 108 (86–123) 0.001*
Working memory index 102 (82–135) 0.06
Processing speed index 100 (79–129) 0.25
Zurich Neuromotor Assessment
Timed performances
Pure motor 0.1 (−2.4 to 4.6) 0.91 11 % (4/38)
Adaptive fine motor −0.3 (−3.6 to 3.5) 0.18 24 % (9/38)
Adaptive gross motor −0.8 (−7.5 to 2.5) 0.012* 34 % (13/38)
Static balance −0.2 (−2.9 to 1.7) 0.13 11 % (4/38)
Associated movements –1.2 (−3.2 to 2.0) <0.001* 39 % (15/38)
*Significant difference at p< 0.05
Results are presented as the median score with the range given in
parenthesis. Comparison is to test norms (mean IQ 100, standard devia-
tion 15)
STEC-HUS, Escherichia coli hemolytic uremic syndrome
a <P10 indicates the proportion of patients presenting with z-scores of<
−1.282 (i.e. results<10th percentile)
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outcome. We report here our results from a single-center
cross-sectional investigation assessing neurocognitive and
neuromotor long-term outcome of pediatric patients after
STEC-HUS, P-HUS or aHUS. In our study we also examined
the role of CNS involvement during the acute episode of HUS
on subsequent neurodevelopment. In contrast to previous
studies focusing on STEC-HUS [17–19], we expressly includ-
ed patients with different HUS forms (STEC-HUS, P-HUS
and aHUS) even though apart from thrombotic microangiop-
athy the underlying pathomechanisms of these HUS forms do
differ.
Our patient series showed an overall favorable
neurodevelopmental outcome after a history of HUS, with a
normal full-scale IQ. Furthermore, the intellectual perfor-
mance of our patients was not affected by CNS impairment
during the acute HUS episode. Only socioeconomic status
was positively correlated with full-scale IQ, which is consis-
tent with findings in healthy controls [26]. Socioeconomic
status is also a strong predictor of intellectual outcome in other
populations at risk, such as preterm born children [31] or
children with congenital heart defects [32].
One-third of our study patients presented with neurological
symptoms during the acute episode of HUS, particularly in the
form of seizures and altered consciousness, including four of
the six patients with P-HUS, but none of those with aHUS.
These findings are consistent with those of previous studies on
neurological involvement in patients with STEC-HUS (19–
30 % showing neurological symptoms) [2, 9, 33] and P-HUS
patients (16–56 % with neurological symptoms) [14, 34, 35].
There are no evidence-based guidelines on the treatment of
CNS complications in HUS. Nathanson et al. [16] suggested
that plasmapheresis might have some benefit in children with
severe CNS complications. In our series, only two children
with STEC-HUS underwent plasmapheresis for severe neuro-
logical complications with full neurological recovery.
Our findings are consistent with the results of three previ-
ous studies. Schlieper et al. [17] demonstrated a favorable
neurocognitive outcome in children at a mean age of 8.6 years
(±3.1 SD) and mean duration of 4.1 years (±2.4 SD) after the
diagnosis of HUS, with normal full-scale and subscale IQ
values in 91 children after HUS (without specification of
HUS type), including nine children with seizures or coma
during the acute episode of HUS. However, these authors
did observed mild deficits in language domains in patients
with severe acute HUS [17]. Qamar et al. [18] described a
normal intellectual outcome in all seven patients studied de-
spite severe neurological complications during the acute dis-
ease. Bauer et al. [19] also reported a favorable neurocognitive
outcome in 25 children affected by the STEC-HUS outbreak
in 2011 in Germany due to E. coli O104:H4. However, these
authors observed a slightly lower full-scale IQ in children with
CNS involvement vs. those without CNS involvement during
HUS. Other studies focusing on neurological involvement in
adult patients with STEC-HUS due to E. coli O104:H4 also
suggested a good neurological outcome [36].
In our series, only six children (12 %), including four with
ESRD, had a full-scale IQ of <85, indicating an unfavorable
intellectual outcome. Moreover, two of these six children had
a history of severe cerebral complications after P-HUS.
Patients with a history of ESRD showed a significant
poorer neurocognitive outcome after HUS compared to pa-
tients without ESRD after HUS. The development of ESRD,
particularly in infancy, is a known risk factor for impaired
neurocognitive outcome [37].
In our study, neuromotor performance was less favorable
than intellectual outcome, with a poorer outcome particularly
in fine and gross motor functioning, static balance and move-
ment quality. Normal performance observed in the domain of
pure motor functioning. This is an interesting finding. In this
domain, simple motor tasks, such as repetitive or sequential
finger, hand or foot movements, are performed. It is conceiv-
able that impairments only become apparent when more com-
plex motor functions, such as adaptive motor performances,
are required. Motor performance did not differ between chil-
dren with and without CNS impairment during acute HUS
episode. Qamar et al. [18] also studied neuromotor outcome
after HUS, reporting impaired fine motor and clumsiness in
four of seven patients with severe neurological complications
during the acute HUS episode. In our study, a significant
proportion of patients (15–38 %) had motor performance
below the 10th percentile. This poorer motor performance is
clinically significant as children who perform below the 10th
percentile often have difficulties participating in activities of
daily life and demonstrate poorer hand writing skills and
slower speed. However, we did not assess the impact of motor
difficulties on daily life. Of note, motor therapies were report-
ed in 19 % of our patients independently of CNS involvement
during HUS.
The pathophysiological mechanisms leading to impaired
neuromotor outcome after HUS remain to be clarified. In
addition to cerebral thrombotic microangiopathy, factors such
as electrolyte imbalances (e.g. severe hyponatremia), hypo-
osmolality, azotemia, arterial hypertension and the direct toxic
effects of Shiga toxin in STEC-HUS may be involved in
pathogenetic mechanisms of neurological impairment [19,
38]. Impaired neuromotor outcome can also be found in other
cohorts of pediatric patients with various diseases, such as
congenital diaphragmatic hernia [39] or congenital heart dis-
ease [40]. Impaired neuromotor findings also suggest disease-
unrelated factors leading to an adverse neuromotor perfor-
mance, such as factors attributable to long hospital stay sec-
ondary to more severe course of a disease or more parental
protection and less experience.
This study has several limitations. Due to its retrospective
and cross-sectional study design, information on neurological
complications during the acute illness phase was obtained
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retrospectively by chart review and parental interviews. Apart
from the parents’ medical report, no formalized data on the
neurodevelopmental status prior to HUS were available.
Furthermore, the number of patients with P-HUS and aHUS
was too small to analyze outcome in relation to HUS type.
In conclusion, the results of this study show that children
and adolescents with HUS have a normal intellectual out-
come, but a significant impairment in motor outcome.
Neurological complications during the acute episode of HUS
were not associated with a poorer neurodevelopmental out-
come. Therefore, long-term observation of children after HUS
is advisable for the early detection of neurodevelopmental
deficits.
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Abstract
Background In children after haemolytic-uraemic syndrome
(HUS), little is known about long-term health-related quality
of life (HRQoL) and psychological adjustment as defined by
behavioural problems, depressive symptoms and post-
traumatic stress symptoms.
Methods Sixty-two paediatric patients with a history of HUS
were included in this study. Medical data of the acute HUS
episode were retrieved retrospectively from hospital records.
Data on the clinical course at study investigation were
assessed by clinical examination and laboratory evaluation.
HRQoL and psychological adjustment data were measured
by standardised, parent- and self-reported questionnaires.
Results Haemolytic-uraemic syndrome was diagnosed at a
mean of 6.5 years before the initiation of the study (standard
deviation 2.9, range 0.1–15.7) years. Among the preschool
children, parents reported that their child was less lively and
energetic (HRQoL emotional dimension), while no increased
behavioural problems were reported. In the school-age chil-
dren, self- and proxy-reported HRQoL was well within or
even above the norms, while increased total behavioural prob-
lems were found. The school-age children reported no in-
creased depression scores. Also none of the children met the
criteria for full or partial HUS-associated posttraumatic stress
disorder.
Conclusions Healthcare providers should be particularly alert
to behavioural problems in school-age children with a history
of HUS and to lower HRQoL in preschool children.
Keywords Kidney disease . Outcome . Behavioural
problems . Depression . Post-traumatic stress disorders .
Paediatric patients
Introduction
Haemolytic-uraemic syndrome (HUS) is a systemic and
life-threatening disease, and one of the main causes of
acute kidney injury in children [1]. Most paediatric pa-
tients suffer from typical, infection-mediated forms of
HUS [i.e. shigatoxin-associated HUS (STEC-HUS) or
Streptococcus pneumoniae-associated HUS (P-HUS)]
[2–5]. In the acute phase of the disease, many patients
need treatment in an intensive care unit (ICU) and di-
alysis. While renal function recovers in the majority of
HUS patients, a few patients develop chronic kidney
disease (CKD), leading to end-stage renal disease
(ESRD) [3, 5, 6]. Thus, HUS patients are at risk of late
and long-term renal and extra-renal complications, such
as neurological sequelae, visual disorders and diabetes
mellitus [2], that may be very stressful and impact the
patients’ health-related quality of life (HRQoL) and psy-
chological adjustment.
HRQoL and psychological adjustment have become two
important outcome measures to evaluate the impact of a
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disease on an individual patient. While HRQoL is a multi-
dimensional concept that focuses on the subjective per-
ception of physical, emotional, social and cognitive di-
mensions of health [7], psychological adjustment targets
the individual’s mental health by asking about the pres-
ence or absence of behavioural problems and/or psycho-
logical symptoms (e.g. depression) [8]. In contrast to
the well-described medical outcome of HUS [2–6, 9],
little is known about the psychological outcome and
HRQoL in children after HUS. The few studies which
have been conducted [9–11] indicated good psychologi-
cal adjustment as measured by child behavioral prob-
lems 4 years after the acute HUS episode, but none of
these studies examined the child’s HRQoL. In recent
years, HRQoL has been mainly studied in paediatric
patients with CKD, including kidney transplant recipi-
ents, with the results indicating that their HRQoL was
lower than that of healthy controls [12–19]. Research on
determinants of HRQoL has revealed that transplant re-
cipients have better HRQoL than dialysis patients [16,
19], while the results for differences in HRQoL between
patients on conservative treatment and dialysis are in-
consistent [12–14]. Higher proportions of behavioural
and emotional disorders among paediatric patients with
CKD have also been shown [15, 20–24]. However,
none of these studies with CKD patients, as well as
with children with a history of HUS, examined posttrau-
matic stress symptoms. Since HUS is a life-threatening
event, children may be traumatised and subsequently
develop posttraumatic stress symptoms or even posttrau-
matic stress disorder (PTSD), as based on the diagnostic
criteria of the Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) [25].
The aims of the study reported here were threefold.
Firstly, we wanted to examine self- and proxy-reported
HRQoL in children with a history of typical and atyp-
ical HUS forms, as compared to healthy controls. A
lower HRQoL was expected in long-term survivors of
HUS as these children are at risk of severe complica-
tions. Secondly, we wanted to describe the psychologi-
cal adjustment of these children by examining parent-
reported behavioural problems, self-reported depressive
symptoms and PTSD symptoms in school-age children
only. We assumed that behavioural problems were more
common in these children than in age-matched healthy
controls and that a small proportion of school-age chil-
dren would report depressive symptoms and PTSD
symptoms secondary to HUS. This was also hypothe-
sized based on the fact that HUS patients are at risk
of late and long-term renal and extra-renal complica-
tions which might negatively impact the patients’ psy-
chological adjustment. Thirdly, we aimed to examine
associations between children’s medical characteristics
and long-term HRQoL and psychological adjustment.
We expected to identify lower HRQoL and lower psy-
chological adjustment in patients with current lower re-
nal function.
Methods
Participants and procedure
This cross-sectional study was part of a comprehensive single-
centre data collection process on long-term renal, neuro-
developmental and psychosocial outcomes in paediatric pa-
tients with a history of HUS [26, 27]. The study was approved
by the Ethics Committee and registered at ClinicalTrials.gov
(NCT 01666548). For this study, children and adolescents
with a diagnosis of HUS based on current HUS nomenclature
[28] and treated at the Paediatric Nephrology Unit of the
University Children’s Hospital Zurich between April 1995
and February 2013 were recruited between February 2012 to
February 2013. Children with severe mental retardation (e.g.
with trisomy 21) before the episode of HUS and children
aged <18 months or >17 years at the time of assessment were
excluded from this study.
Overall, 107 children with a HUS history were eligible for
study participation. Of these, 45 children did not participate
for the following reasons: child deceased before inclusion
(n = 7), insufficient knowledge of German (n = 1), lost to
follow-up (n = 16), siblings (n = 3; both siblings took part in
the study, but only 1 child was included in the analysis be-
cause parent-reported data on HRQoL and psychological ad-
justment are correlated in these cases) and no reasons given
(n = 18). Ultimately, 62 children participated in this study (re-
sponse rate 58%). All parents of these children signed the
informed consent form. The 62 participants did not differ from
the 45 non-participants in terms of sex (χ2 = 0.10, p = 0.84),
age at HUS diagnosis (U = −0.98, p = 0.33), type of HUS
classification (χ 2 = 0.75, p = 0.45), need of dialysis during
acute HUS (χ 2 = 0.09, p = 0.84), length of hospital stay dur-
ing acute HUS (U = −0.21, p = 0.84), development of CKD at
study investigation (χ 2 = 0.43, p = 0.54) and socioeconomic
status (SES; U = −0.31, p = 0.76).
After receiving written informed consent, the child’s med-
ical data on the acute HUS episode were retrieved retrospec-
tively from the patient’s hospital records. Upon inclusion in
the investigation, all children underwent clinical examination
and laboratory evaluation. All parents were asked to complete
standardised questionnaires on their child’s HRQoL and psy-
chological adjustment. Self-reported HRQoL and psycholog-
ical adjustment of children aged >6.5 years were obtained by
standardised questionnaires filled in by an experienced paedi-
atrician in a face-to-face interview with the patient. An
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overview of all outcomemeasures assessed in the study can be
found in Table 1.
Measures
Medical data
Haemolytic-uraemic syndrome has been defined as the occur-
rence of non-immune haemolytic anemia, thrombocytopenia
and features of acute renal injury [26]. The diagnosis of HUS
was confirmed in all patients by paediatric nephrologists and
classified as (1) typical, infection-mediated HUS, including
STEC-HUS and P-HUS, or as (2) atypical HUS (aHUS) based
on hereditary and/or acquired disorders of regulation of the
alternative complement system. Neurological involvement
during acute HUS included seizures, altered consciousness,
ataxia, muscle tone abnormalities, hemiplegic symptoms, dys-
arthria, visual disorders, movement disorders and vestibular
symptoms [26]. Long-term renal sequelae included the pres-
ence of CKD, as defined according to the Kidney Disease
Outcomes Quality Initiative of the National Kidney
Foundation [29]. Glomerular filtration rate as a marker of
renal function and its classification into the five CKD stages
was evaluated using the Schwartz formula with the local fac-
tor k of 40 for all children and with plasma creatinine concen-
tration in micromoles per litre [30]. The time since acute HUS
was calculated by the difference between the child’s age at
study investigation and age at HUS diagnosis.
Health-related quality of life
Health-related quality of life for children aged ≤6.5 years was
assessed by parental report, using an authorised German ver-
sion of the TNO-AZL Preschool Quality of Life
Questionnaire (TAPQOL) [31], and for participants
aged >6.5 years of age using the German parent and child
form of the KIDSCREEN-27 [32].
The TAPQOL is a validated and standardised ques-
tionnaire consisting of 43 items with a recall period of
1 week. The items are classified into 12 scales assessing
four global dimensions of HRQoL: physical functioning
(including information on the child’s sleeping and appe-
tite problems), social functioning (measuring social con-
tacts with other children, such as whether the child was
at ease with other children), cognitive functioning (mea-
suring the communicative skills of the child) and emo-
tional functioning (measuring the child’s level of anxi-
ety, positive mood and liveliness). Scales are trans-
formed into a 0–100 scale, and the four global dimen-
sions are computed by the average of all underlying
scales. To obtain a measure of overall HRQoL, the total
score is computed by averaging the scores of the four
global dimensions. Higher scores indicate better
HRQoL. We retrieved norms from the manual, and
these were based on data from 211 parents of healthy
Dutch children between the ages of 18 months and
5 years [31]. In this study, internal consistency was
good for the total score (Cronbach’s α = 0.80) and for
most scales, except for the scales measuring lung prob-
lems (Cronbach’s α = −0.14) and social functioning
(Cronbach’s α = −0.08), which displayed poor internal
consistencies.
The KIDSCREEN-27 is a validated and standardised ques-
tionnaire assessing self- and proxy reports of HRQoL in chil-
dren ranging in age from 8 to 18 years [33]. It consists of 27
items assessing either the frequency or the intensity of a be-
haviour or a feeling on a 5-point Likert scale, over a recall
period of 1 week. The following five HRQoL dimensions are
computed in KIDSCREEN-27: physical well-being, psycho-
logical well-being, autonomy and parent relations, peers and
social support and school environment. In accordancewith the
manual, scale scores are transformed into T-values based on
international reference data [32]. In our study, T-values were
compared to data from a community sample of >1596 Swiss
Table 1 Overview of long-term outcome measures assessed in the study
Preschool children aged ≤ 6.5 years School-age children aged >6.5 years
Outcome measure Proxy-
reported
Outcome measure Self-
reported
Proxy-
reported
Health-related quality of
life (HRQoL)
TNO-AZL Preschool Quality of Life
Questionnaire (TAPQOL)
x Health-related quality of Life Questionnaire
(KIDSCREEN)
x x
Psychological adjustment
Behavioural problems Child Behaviour Check List (CBCL) for
ages 1.5–5 and 4–18 years
x CBCL for ages 4–18 years - x
Depression - - Child Depression Inventory (CDI) - x
Posttraumatic stress
disorder
- - University of California at Los Angeles
(UCLA) PTSD Reaction Index
- x
PTSD, Posttraumatic stress disorder
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children between the ages of 8 to 18 years. A total score is
computed from the average of the T-values of the five HRQoL
domains. Internal consistency in this study was good for the
total score (Cronbach’s α = 0.87 for both parent- and self-
reported total score) and acceptable to good for the five
HRQoL domain scales (Cronbach’s ranging from α = 0.68 to
α = 0.84 for parent-reported HRQoL scores and from α = 0.61
to 0.72 for self-reported HRQoL scores).
Psychological adjustment
The Child Behaviour Checklist (CBCL) is a validated and
standardised questionnaire assessing parental reports of a
child’s behavioural problems [34, 35]. In this study, two
authorised German versions of the CBCL were used: the
CBCL/1.5-5 for children aged <4 years [36] and the
CBCL/4-18 for children aged ≥4 years [34]. Both instruments
yield scores for internalising behavioural problems (referring
to behaviours in which children direct feelings and emotions
inwards, such as being anxious or depressed, having somatic
complaints or social withdrawal), externalising behavioural
problems (referring to behaviours which are directed outward,
such as being aggressive or delinquent) and an overall score
for total behavioural problems. Higher scores indicate more
behavioural problems, or less psychological adjustment. T-
values are derived from normative data: the T-values of the
CBCL/1.5-5 were calculated based on a community sample of
700 healthy U.S. children [35], the T-values of the CBCL/4-18
were calculated based on 1964 healthy Swiss children [37]. In
the current study, internal consistency for the CBCL/1.5–5 or
CBCL/4-18 was acceptable to good for internalising problems
(Cronbach’s α = 0.82, and α = 0.73, respectively),
externalising problems (Cronbach’s α = 0.79, and α = 0.90,
respectively) and total problems (Cronbach’s α = 0.87, and
α = 0.88, respectively).
The presence and severity of self-reported depressive
symptoms of school-age children only were assessed using
the authorised German version of the Child Depression
Inventory [38], i.e., the BDepressions-Inventar für Kinder
und Jugendliche^ (DIKJ) [39]. The DIKJ is validated for chil-
dren between 8 and 17 years of age and includes 26 items with
three response options for each item, representing the severity
of depression ranging from 0 (no symptoms) to 2 (definite
symptoms). A total score is obtained by summing across all
26 items. Higher values indicate greater depression severity.
Clinically relevant depression was defined by a cut-off score
set at total score of >18 [39]. In the current study, internal
consistency for the total score was acceptable (Cronbach’s
α = 0.69).
PTSD in the school-age children was assessed using the
German child version of the University of California at Los
Angeles (UCLA) PTSD Reaction Index [40] which is validat-
ed for children aged >6 years [41]. The UCLA PTSD provides
a diagnosis of PTSD according to the criteria of the DSM-IV
[25]. The first part of the UCLA PTSD assesses the type of
traumatic event (e.g. having had a life-threatening disease like
HUS) and, in case there were multiple events, the most stress-
ful one. The second part evaluates the circumstances and the
emotions in the context of the trauma. The third part assesses
the frequency of the 20 PTSD symptoms on a 5-point Likert
scale (0–4) with regard to the last month. Symptoms are relat-
ed to the three DSM-IV clusters (i.e. intrusion, avoidance and
hyperarousal). Higher scores indicate greater symptom sever-
ity. The fourth part of the questionnaire assesses the duration
of symptoms and possible functional impairments in different
areas of life (e.g. school and learning). According to the DSM-
IV, criteria for full PTSD are met if the child reports at least
one intrusion symptom, three avoidance symptoms and two
hyperarousal symptoms, as well as duration of these symp-
toms for at least 1 month and impaired function in at least one
life area [25].
Socioeconomic status
Socioeconomic status was assessed on the basis of maternal
education and paternal occupation, ranging from 2 to 12, with
2 being the lowest SES score and 12 the highest. Three social
classes were assigned: lower (SES 2–5), middle (SES 6–9)
and upper (SES 10–12). This measure has proven to be a valid
indicator of SES in previous studies involving the Swiss pop-
ulation [42].
Statistical analyses
Data were analysed using the statistical package SPSS for
Windows, release 22 (IBM Corp., Armonk, NY). All analyses
were performed with two-tailed tests, and p < 0.05 was con-
sidered to be significant. Chi-square tests and Mann–Whitney
U tests were used as appropriate to compare child sex, child
age at HUS diagnosis, type of HUS classifications, need for
dialysis during the acute phase, length of hospital stay during
acute HUS, development of CKD and SES between partici-
pants and non-participants. Cronbach’s alpha was calculated
to test the internal reliability of scale scores. Because most
data showed non-normal distributions according to the
Kolmogorov–Smirnov test, we used Mann–Whitney U tests
for testing the equality of means between preschool and
school-age children. Differences in child HRQoL and psycho-
logical adjustment scores between sample means and norma-
tive data were examined using Mann–WhitneyU tests or one-
sample t tests. These differences were quantified by calculat-
ing effect sizes according to Cohen with a d of 0.20 indicating
a small effect, a d of 0.50 indicating a medium-sized effect and
a d of > 0.80 indicating a large effect [43]. Pearson correlation
was calcula ted to analyse associa t ions between
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sociodemographic variables, medical characteristics, HRQoL
and psychological adjustment scores.
Results
Patient characteristics
Patient characteristics are summarised in Table 2. The major-
ity of the children had a STEC-HUS, while seven children
also had a P-HUS and three school-age children had aHUS.
At the time of HUS diagnosis, the children were on average
2.9 years old [standard deviation (SD) 2.9, range 0.3–14.4)
years. During the acute episode, 43 of the 62 children (69%)
were dialysed; in most cases, dialysis consisted of peritoneal
dialysis. All but five children (92%) were initially treated in
the ICU, with school-age children more frequently treated in
ICU than preschool children. On average, the children stayed
for 24 days in hospital. Neurological involvement was present
in 24 of the 62 children (39%).
The average age of the children at the time of the study
investigation was 9.4 (SD 4.1, range 1.9–16.7) years. Of the
62 children enrolled in the study 26 (42%) had CKD, among
whom 11 had CKD stage 1, nine had stage 2, one had stage 3
and five had ESRD (CKD stage 5). Four children with ESRD
(STEC-HUS, n = 2; P-HUS, n = 1; aHUS, n = 1) had under-
gone successful renal transplantation, while one child with
STEC-HUS was still on the waiting list for renal transplanta-
tion. In addition, four of the 26 patients with CKD (15%) had
severe long-term extra-renal sequelae. One patient had
insulin-dependent diabetes mellitus due to STEC-HUS-
related pancreatitis, one patient had impaired visual acuity
due to retinal bleeding during acute STEC-HUS and two pa-
tients had severe neurodevelopmental impairment due to se-
vere neurological involvement in STEC-HUS and in P-HUS
following pneumococcal meningitis, respectively. Four chil-
dren with normal renal function had been diagnosed with an-
other chronic disease since their HUS diagnosis, i.e. attention
deficit hyperactivity disorder, epilepsy, hearing disorder and
neurodevelopmental delay. Thus, 32 of the 62 children (52%)
had neither renal nor extra-renal sequelae.
Health-related quality of life
Mean values of HRQoL scores for the study sample and
the reference group are listed in Tables 3 and 4 for
preschool children and school-age children, respectively.
Parents of preschool children did not report impaired
overall HRQoL as measured by the TAPQOL. Indeed,
they described their child as having better social func-
tion than the reference group. However, the parents did
report that their preschool-age child had been less lively
and energetic (emotional HRQoL dimension). In
contrast, parents of school-age children reported in-
creased overall HRQoL as well as better psychological
well-being and more supportive interactions with their
peers than the control group. School-age children (child
self-report form) reported all HRQoL dimensions within
norms.
Psychological adjustment
Sample means and reference data for child behavioural prob-
lems are listed in Table 5. Parents of preschool children did not
report that their child had more total behavioural problems
than controls. They even reported significantly fewer
externalising problems. In contrast, parents of school-age chil-
dren with a HUS history reported significantly more total be-
havioural problems than parents of control children. Clinically
relevant internalising problems were reported for one pre-
school child (10%) and four school-age children (9%);
externalising problems above the cut-off for clinically relevant
problems were reported for three school-age children only
(7%).
Data on self-reported depressive and PTSD symptoms
were available for 37 of the 41 school-age children. The aver-
age depression score was 8.5 (SD 5.0, range 0–28). A total
depression score above the cut-off value for clinically relevant
depression was reported for only one patient (3%), a girl with
STEC-HUS and currently normal renal function. In addition,
none of the 37 school-age children perceived HUS as a trau-
matic event and met the criteria for full or partial PTSD ac-
cording to DSM-IV.
Associations between medical data, HRQoL
and psychological adjustment
Bivariate correlations between the child’s socio-demographic
characteristics (age, sex, SES), medical characteristics, long-
term HRQoL and psychological adjustment scores are pre-
sented in Table 6. Among the preschool children, no signifi-
cant associations were found between medical characteristics
and HRQoL or psychological adjustment scores, while par-
ents from lower SES classes exhibited significantly more be-
havioural problems. Among the school-age children, children
with CKD at study investigation self-reported that they had
lower HRQoL than children without CKD. This effect was not
found for parent-reported HRQoL. In addition, longer periods
in ICU, length of dialysis and length of periods in hospital
were related to more total behavioural problems in the
school-age children. These medical characteristics were not
significantly associated with self-reported depressive symp-
toms, while a shorter time since HUS diagnosis was associat-
ed with more depressive symptoms.
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Discussion
We have investigated both HRQoL and psychological adjust-
ment in children with a history of HUS and the associations
between these two outcome measures and the child’s medical
characteristics. Our results indicate that, on average 6.5 years
after acute HUS, self- and proxy-reported HRQoL of school-
age children was well within or even above the norms, while
some psychological maladjustment, as measured by the
CBCL, was present. Among the preschool children, parents
reported that their child was less lively and energetic (emo-
tional HRQoL dimension) while no increase was found in
behavioural problems.
In contrast to our hypothesis, overall HRQoL of the chil-
dren with a history of HUS was not impaired. As none of the
previous studies with paediatric patients with a history of HUS
examined HRQoL, we were not able to compare this result
with any data reported in the literature. Our result that parents
Table 2 Characteristics of
paedriatic patients with
haemolytic-uraemic syndrome
enrolled in this study
Patient characteristicsa Total sample
(n = 62)
Preschool
children (n = 21)
School-age
children (n = 41)
pb
Age at investigation (years) 9.4 (4.1)
[1.9–16.7]
4.7 (1.4)
[1.9–6.5]
11.8 (2.7)
[6.75–16.7]
<0.001
Female gender 35 (57%) 12 (57%) 23 (56%) 0.94
Type of HUS classification
STEC-HUS 52 (84%) 18 (86%) 34 (83%) 0.20
P-HUS 7 (11%) 3 (14%) 4 (10%)
aHUS 3 (5%) 0 3 (7%)
Age at diagnosis (years) 2.9 (2.9)
[0.3–14.4]
1.9 (1.0 )
[0.3–4.1]
3.4 (3.4)
[0.4–14.4]
0.28
Time since acute HUS (years) 6.5 (4.1)
[0.1–15.7]
2.8 (1.7)
[0.1–6.1]
8.4 (3.6)
[0.3–15.7]
<0.001
Socioeconomic status 8.4 (2.1)
[2–12]
8.1 (1.8) [4-12] 8.5 (2.3) [2–12] 0.39
Medical characteristics during acute episode of HUS
Dialysis 43 (69%) 13 (62%) 30 (68%) 0.36
Peritoneal dialysis 32 (74%) 9 (69%) 23 (77%)
Haemofiltration/haemodialysis 8 (19%) 4 (31%) 4 (13%)
Combination of peritoneal and
haemofiltration/haemodialysis
3 (7%) 0 3 (10%)
Duration of dialysis (days) 10.3 (14.3)
[0–79]
10.0 (16.9)
[0–78]
10.5 (13.1)
[0–79]
0.38
Stay in ICU 57 (92%) 17 (81%) 40 (98%) 0.02
Duration of stay in ICU (days) 8.2 (7.3)
[0–31]
7.9 (7.3) [0–22] 8.3 (7.4) [0–31] 0.75
Duration of hospital stay (days) 23.7 (17.7)
[5–97]
21.7 (18.7)
[5–92]
24.8 (17.3)
[5–97]
0.33
Neurological involvement 24 (39%) 9 (43%) 15 (37%) 0.63
Clinical course at investigation
CKD 26 (42%) 7 (33%) 19 (46%) 0.33
Stage 1 11 (42%) 5 (36%) 6 (32%)
Stage 2 9 (35%) 1 (7%) 8 (42%)
Stage 3 1 (4%) 0 1 (5%)
Stage 4 0 0 0
Stage 5 5 (19%) 1 (7%) 4 (21%)
CKD and other long-term extra-renal
sequelae
4 (15%) 2 (29%) 2 (11%) 0.48
Not HUS-related comorbidities 4 (7%) 1 (5%) 3 (7%) 0.70
HUS, Haemolytic-uraemic syndrome; STEC-HUS, shigatoxin-associated HUS; P-HUS, Streptococcus
pneumoniae-associated HUS; aHUS, atypical HUS; CKD, chronic kidney disease; ICU, intensive care unit
a Values in table are presented as a number with the percentage in parenthesis or as the mean with the standard
deviation (SD) in parenthesis and the range in square brackets
bMann–Whitney U tests were performed for continuous variables and χ2 tests were performed for nominal
variables (all dichotomised)
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rated their child’s HRQoL as similar to or even better than the
norms might be explained by the possibility that they rated
their child’s current HRQoL in comparison to that of when
their child was sick. Our result is indeed in contrast to those of
several studies indicating lower HRQoL in paediatric patients
with CKD compared to healthy controls [12–19]. In our study,
42% of the children had CKD, among whom four had already
undergone renal transplantation and one child was still on the
waiting list for renal transplantation. This lower rate of CKD
patients might explain the better HRQoL reports in our study.
However, our results are in line with a study that showed no
difference in long-term HRQoL in children 3–5 years of age
after acute renal failure of various causes (e.g. due to nephro-
toxicity) [44]. Thus, children with a history of HUS, even
Table 3 Sample means and
reference data for health-related
quality of life in preschool
children with a history of
haemolytic-uraemic syndrome
Measure Sample Reference group a Statistics
n Mean SD Mean SD pb dc
TAPQOL parent form
Physical functioning
Sleeping 21 83.1 16.6 84.3 15.7 0.79 −0.07
Appetite 20 85.8 23.4 85.2 11.9 0.06 0.03
Lung problems 20 96.3 8.8 97.7 7.8 0.18 −0.17
Stomach problems 18 86.1 17.2 92.4 13.2 0.08 −0.41
Skin problems 21 88.5 15.7 92.6 10.4 0.55 −0.31
Motor functioning 20 94.1 22.5 98.8 3.7 0.84 −0.29
Physical dimension score 16 90.8 6.4 91.9 5.6 0.51 −0.18
Social functioning
Social functioning 20 95.8 10.6 91.4 15.1 0.13 0.34
Problem behavior 21 79.8 19.2 66.0 15.1 0.001 0.80
Social dimension score 20 87.5 9.6 78.7 10.4 0.001 0.88
Cognitive functioning
Communication 20 92.8 15.4 91.8 9.8 0.15 0.07
Emotional functioning
Anxiety 20 83.3 21.6 78.6 17.9 0.18 0.24
Positive mood 20 97.5 8.2 99.0 5.7 0.20 −0.21
Liveliness 20 90.0 18.3 97.8 8.3 0.002 −0.55
Emotional dimension score 20 90.3 12.3 91.8 7.4 0.53 −0.14
Total HRQoL score 16 86.4 10.5 82.9 7.4 0.09 0.38
Higher scores indicate better HRQoL
a Reference group according to Bisegger et al. [32]
b One sample t tests were performed
c Effect size according to Cohen [43]
Table 4 Sample means and
reference data for health-related
quality of life in school-age
children with a history of
haemolytic-uraemic syndrome
Measure Sample Reference group a
n Mean SD Mean SD pb dc
KIDSCREEN-27 parent proxy-report form
Physical well-being 34 54.6 10.8 52.8 8.7 0.34 0.18
Psychological well-being 34 56.3 10.6 51.9 9.0 0.022 0.45
Autonomy & parents 34 54.9 8.3 53.1 8.4 0.22 0.22
Peers & social support 34 55.1 8.0 51.0 8.1 0.005 0.51
School environment 33 54.8 8.6 52.5 8.9 0.14 0.26
Total score 33 55.3 6.2 52.0 9.0 0.005 0.43
KIDSCREEN-27 child self-report form
Physical well-being 37 50.4 7.7 52.7 9.0 0.07 −0.28
Psychological well-being 37 53.3 7.2 53.1 9.3 0.86 0.02
Autonomy & parents 37 52.7 8.5 53.4 8.8 0.64 −0.08
Peers & social support 37 52.1 7.9 51.0 9.0 0.40 0.13
School environment 37 54.9 7.0 53.0 9.0 0.11 0.24
Total score 37 52.7 5.4 52.8 9.2 0.90 −0.01
Higher scores indicate better HRQoL
aReference group according to Bisegger et al. [32]
b One-sample t tests were performed
c Effect size according to Cohen [43]
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severe cases of HUS, might recover quite well in the long-
term, and a patient’s acute medical characteristics (e.g. longer
length of stay in ICU in severe cases) might have a minor
impact on long-term HRQoL. Our data indicate that neither
medical characteristics during an acute episode nor the pres-
ence of CKD were significantly associated with impaired
HRQoL reported by the parents. In contrast, our study showed
that lower self-reported HRQoL among the school-age chil-
dren was associated with the presence of CKD.
With regard to psychological adjustment, the parents of our
study cohort reported increased total behavioural problems for
school-age children, but not for preschool children, with the
parental reports for the latter group even indicating signifi-
cantly fewer externalising problems. This is in contrast to
previous studies which found no clinically significant total
behavioural problems in children with a history of HUS
[9–11]. Possible factors to explain these differences include
the longer time period since acute HUS in the CKD patients
and the increased number of children affected by CKD. Thus,
especially school-age children with a history of HUS seem to
be at risk of psychological maladjustment as measured by the
CBCL. Among these children, a longer stay in the ICU as well
as longer periods of dialysis and hospital staywere significant-
ly associated with more parent-reported total behavioural
problems in our study. Thus, these medical characteristics
can be seen as risk factors for long-term psychological mal-
adjustment in children with a history of HUS. Among the
school-age children, only one female child with a history of
STEC-HUS reported clinically relevant depressive symptoms.
However, we cannot prove a direct association with the HUS
episode. In fact, none of the school-age children perceived
Table 6 Correlations between child socio-demographic characteristics, medical characteristics, health-related quality of life and psychological ad-
justment scores
Patient
characteristics
Preschool children School-age children
HRQoL Psychological
adjustment
HRQoL Psychological adjustment
Parent-reported
TAPQOL total score
(n = 16)
Parent-reported
CBCL total score
(n = 11)
Parent-reported
KIDSCREEN total
score (n = 33)
Self-reported
KIDSCREEN total
score (n = 37)
Parent-reported
CBCL total score
(n = 36)
Self-reported
CDI total score
(n = 37)
Age at study
investigation
−0.30 0.41 −0.18 −0.03 −0.19 0.10
Sex −0.15 −0.01 0.08 −0.14 −0.13 0.17
Socioeconomic
status
0.15 −0.72* −0.36* 0.12 0.05 −0.06
Type of HUS
classification
NA NA −0.10 −0.15 0.19 −0.09
Time since HUS
diagnosis
−0.13 0.08 0.15 0.10 −0.21 −0.37*
Length of stay in
intensive care
unit
−0.18 0.22 −0.21 −0.11 0.33* −0.03
Length of
dialysis
−0.08 0.20 −0.12 −0.05 0.49** −0.11
Length of
hospital stay
−0.06 0.17 −0.13 −0.22 0.56*** −0.14
Neurological
involvement
0.26 −0.11 0.01 0.01 0.07 −0.03
CKD at study
investigation
0.16 0.07 −0.23 −0.35* 0.14 −0.24
*p < 0.05, **p< 0.01, ***p ≤ 0.001
NA, Not applicable (no preschool child was affected by typical HUS)
Table 5 Sample means and reference data for behavioural problems of
children with a history of haemolytic-uraemic syndrome
Measure Sample Reference groupa
n Mean SD Mean SD pb dc
CBCL 1.5-5 parent
proxy-report form
Internalising score 10 48.2 14.8 50.0 10.0 0.71 −0.15
Externalising score 9 41.3 6.3 50.0 10.0 <0.01 −1.04
Total score 11 43.8 10.2 50.0 10.0 0.07 −0.61
CBCL 4-18 parent
proxy-report form
Internalising score 45 48.4 10.4 50.0 10.0 0.32 −0.16
Externalising score 46 47.4 9.9 50.0 10.0 0.09 −0.26
Total score 46 55.4 6.5 50.0 10.0 <0.001 0.64
a Reference group of the CBCL 1.5-5 according to Achenbach and
Rescoria [35] and of the CBCL 4-18 according to Steinhausen et al. [37]
b One-sample t tests were performed
c Effect size according to Cohen [43]
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HUS as a traumatic event and met the criteria for full or partial
PTSD according to DSM-IV [25]. This is in contrast to the
parents, some of whommet the criteria for full or partial PTSD
diagnosis [27].
The strengths of this study include the use of well-validat-
ed, multidimensional and standardised questionnaires with
reference data, the assessment of self- and proxy-reports and
the inclusion of children with a broad spectrum of ages and
HUS types. Nevertheless, several limitations merit note.
Firstly, the cross-sectional design of our study prevents us
from drawing any conclusion about causal relations, and we
were not able to describe the course of HRQoL or psycholog-
ical adjustment over time. Secondly, our study included only a
small number of preschool children, with no preschool child
being affected by an aHUS. Thus, we were not able to provide
data on long-term HRQoL and psychological adjustment sep-
arately for patients affected by typical and atypical HUS.
Looking on mean differences among the school-age children
only, it can be assumed that HRQoL and psychological ad-
justment might be lower in patients with a history of aHUS
(data not shown). Thus, further studies are necessary to ana-
lyze HRQoL and psychological adjustment separately for the
different HUS forms. However, post-hoc power analysis (α =
0.05, two-tailed) using the G*power software [45] indicated
that, for each t test comparing sample means with normative
data, the power to detect a large effect size (d = 0.80) was
adequate for the TAPQOL (0.87), but just below the recom-
mended 0.80 level for the CBCL 1.5-5 (0.75) [43]. For the
school-age group, the power to detect a large or a medium
effect size was adequate in each analysis, but not adequate to
detect small effect sizes. Thus, our sample sizes provided ad-
equate power at the medium to large effect size level, but not
sufficient power at the small effect size level. Thirdly, the
appropriateness can be questioned of using Dutch norms for
the TAPQOL and U.S. norms for the CBCL 1.5-5. Slight
differences with respect to child and parents’ age, SES and
cultural background may compromise comparability.
However, there are no Swiss or German reference values
available for these two measures, and previous findings sup-
port the use of U.S. norms for the CBCL in German samples
[46]. Fourthly, no self-reports of child behavioural problems
were assessed, which might have provided an insight into
whether the parents underestimated the impact of CKD on
their child’s psychological adjustment. Fifthly, we were un-
able to control for confounding factors due to the small sample
size for self- and/or proxy-reportedHRQoL and psychological
adjustment.
We previously recommended that healthcare providers
should pay special attention to parents’ reports of PTSD
symptoms during the clinical follow-up of a child with HUS
[27]. Based on the results of our current study, we further
recommend that healthcare providers be especially alert for
any signs of behavioural problems in school-age children with
a history of HUS and for of lower HRQoL in the preschool
children.
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Abstract
Background Little is known about health-related quality of
life (HRQoL) and mental health of parents having children
with a history of hemolytic uremic syndrome (HUS).
Methods This study included 63 mothers and 58 fathers of a
cohort of 63 HUS-affected children. At assessment, the mean
time since a child experienced an acute episode of HUS was
6.4 years. Parental HRQoL, mental health and posttraumatic
stress disorder (PTSD) were assessed with standardized self-
report questionnaires. Medical data were extracted from pa-
tients’ hospital records.
Results The HRQoL and mental health of both the mothers
and fathers were not impaired compared to normative data.
However, a shorter time since a child’s acute HUS episode
was a significant predictor of lower HRQoL among the
mothers, while no such effect was found among the fathers.
Two fathers (3 %), but no mothers, met the criteria for a diag-
nosis of HUS-related full PTSD; one father (2 %) and four
mothers (6 %) met the criteria for a diagnosis of HUS-related
partial PTSD.
Conclusions Our study shows that most parents of our study
sample were doing well in terms of HRQoL and mental
health, although a small number met the criteria for full or
partial PTSD diagnosis due to their child’s HUS.We therefore
recommend that healthcare providers pay special attention to
parents regarding PTSD symptoms during the clinical follow-
up of a HUS-affected child since some parents may benefit
from psychological support.
Keywords Posttraumatic stress disorder . Nephrology .
Psychology . Outcome . Pediatric . Parents
Introduction
Hemolytic uremic syndrome (HUS) is a systemic, life-
threatening disease that usually occurs in previously healthy
children and is one of the commonest causes of acute kidney
injury in childhood [1]. Most patients are affected by typical,
infection-mediated HUS types [i.e. Shigatoxin-associated
HUS (STEC-HUS) or Streptococcus pneumoniae-associated
HUS (P-HUS)] and recover in the majority of cases after ap-
propriate treatment [2–4]. However, about 5–10 % of patients
die during the acute phase of the disease while others develop
chronic kidney disease (CKD) ranging from preserved kidney
damage with normal renal function to end-stage renal disease
(ESRD) requiring renal replacement therapy [2–7]. In addition
to renal sequelae, HUS may be complicated by long-term
extrarenal sequelae, such as neurological impairment, gastro-
intestinal complications, diabetes mellitus or visual disorders
[2–4, 8–10].
For most parents, the experience of watching their child
endure a HUS episode combined with the strains of a hospital
stay with frequent need of intensive care treatment, the neces-
sity of regular follow-up assessments at the hospital and the
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fear of long-term sequelae may be stressful and possibly neg-
atively influence their health-related quality of life (HRQoL).
HRQoL is a multidimensional concept integrating the subjec-
tive perception of an individual’s physical, psychological and
social function [11]. To date, no study has described the
HRQoL of parents having children with a history of HUS,
irrespective of the clinical course of the disease. Most avail-
able studies have analyzed parental HRQoL in the context of
advanced pediatric CKD, with the results showing that parents
of these children have an increased risk of low HRQoL
[12–16]. A previous qualitative study of parents of children
with a history of STEC-HUS indicated that the parents may
also experience increased emotional distress [17]. Thus, it
would appear that parents of children with a history of HUS
may be at risk of impaired mental health. Additionally, since
HUS is an acute life-threatening disease, parents may be trau-
matized and subsequently develop posttraumatic stress symp-
toms or even posttraumatic stress disorder (PTSD) based on
the diagnostic criteria of the Diagnostic and Statistical Manual
of Mental Disorders, 4th Edition (DSM-IV) [18]. PTSD is
characterized by psychological reactions following exposure
to a traumatic event that are assigned to three symptom clus-
ters (intrusion, avoidance and hyperarousal). A number of
studies have reported a high prevalence of PTSD among par-
ents of children with various life-threatening diseases [19–21].
However, no such information is currently available for par-
ents with HUS-affected children.
The aims of the present study were to investigate the
HRQoL and mental health of parents having children with
HUS as compared to normative data, as well as to assess
the prevalence of parental HUS-related PTSD. Knowledge
of such impairments might help to identify those aspects
of the clinical experience which most strongly affect the
parents and, if necessary, to enable these parents to be
monitored more closely in future. This, in turn, may help
the child to adjust to the disease, as it has been shown that
parents with increased problems may be too absorbed in
regulating their own feelings to be able to provide sensi-
tive support for their child [22]. Based on the findings of
previous studies with parents of children with other sud-
denly occurring diseases [23, 24] or with advanced stages
of CKD [12, 13], we hypothesized that mothers and fa-
thers of HUS-affected children would report a lower
HRQoL compared to normative data and that this would
be especially evident among the parents of children with
atypical HUS (aHUS) and P-HUS, since the course of
their disease may be more severe than that of children
with typical HUS. Furthermore, taking into account pre-
vious investigations of PTSD in parents of children with
various life-threatening and/or chronic diseases [19–21],
we expected impaired mental health and the presence of
HUS-related PTSD symptoms in both the mothers and
fathers of HUS-affected children.
Methods
Study population and procedures
Parents whose children were treated at the Pediatric Nephrol-
ogy Unit of the University Children’s Hospital Zurich be-
tween April 1995 and February 2013 were recruited for this
study which covered the period from February 2012 to Feb-
ruary 2013. The inclusion criteria were (1) diagnosis of pedi-
atric HUS based on current HUS nomenclature [25, 26] and
(2) child age of <18 years during the 1-year recruiting period.
Overall, 115 families with at least one HUS-affected child
aged <18 years were treated in our unit during the recruiting
period. Thirty-two families were excluded from the study for
the following reasons: death of their child during an acute
episode of HUS (n=7), loss to follow-up (n=18), insufficient
knowledge of German language (n=3) and having more than
one HUS-affected child, which differentiates them from all
other families, especially with respect to the level of parental
stress (n=4). Ultimately, 83 families (100 %) with one HUS-
affected child were eligible for the study. The 32 excluded
children did not differ significantly from the 83 eligible chil-
dren with regard to sex, age at HUS diagnosis, need of dialysis
during acute HUS, length of hospital stay, development of
ESRD or socioeconomic status (SES). Of the 83 families, 20
declined to participate in the study (response rate 76 %). The
final sample therefore included 63mothers and 58 fathers with
one HUS-affected child. The 20 children of the non-
participating families did not differ significantly from the 63
children of the participating families with regard to sex, age at
HUS diagnosis, need of dialysis during acute HUS, length of
hospital stay, development of ESRD or SES.
This cross-sectional investigation was part of a comprehen-
s i v e s i n g l e - c e n t e r s t u d y o f l o n g - t e rm r e n a l ,
neurodevelopmental and psychosocial outcomes in pediatric
patients with a history of HUS. The study was approved by the
Ethics Committee of the Canton of Zurich and registered at
ClinicalTrials.gov (NCT 01666548). After receiving written
informed consent, parents were asked to complete the ques-
tionnaires described below. Medical data relating to the acute
HUS episode were retrieved retrospectively from the patients’
hospital records. For assessment of the clinical course after
HUS, all children underwent a clinical examination during
the recruiting period. Parental data were also assessed within
this period.
Child medical data
Hemolytic uremic syndrome has been defined as the occur-
rence of non-immune hemolytic anemia, thrombocytopenia
and features of acute renal injury [26]. The diagnosis of
HUS was confirmed in all patients by pediatric nephrologists
and categorized as (1) typical, infection-mediated HUS,
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including STEC-HUS and P-HUS, or aHUS based on hered-
itary and/or acquired disorders of regulation of the alternative
complement system.
The Medical data assessed included age at disease onset,
requirements, mode and duration of dialysis, length of hospi-
tal stay, duration of stay in the intensive care unit during acute
HUS, development of ESRD, and the need of chronic renal
replacement therapy including dialysis and renal transplanta-
tion. CKD was defined according to the Kidney Disease Out-
comes Quality Initiative of the National Kidney Foundation
[7]. Glomerular filtration rate as a marker of renal function and
its classification into the five CKD stages was evaluated based
on the Schwartz formula using the local factor k of 40 for all
children and plasma creatinine concentration expressed in mi-
cromoles per liter [27].
Parental HRQoL
Self-reported HRQoL was assessed for the 4 weeks immedi-
ately preceding assessment using the authorized German ver-
sion [28] of the Medical Outcomes Study Short Form-36 item
questionnaire (SF-36) [29]. The SF-36 includes eight sub-
scales, namely, physical functions (e.g. difficulty going up
stairs), role physical (e.g. difficulties at work due to physical
problems), bodily pain (e.g. to what extent pain would restrict
everyday activities), general health (e.g. how the general
health would be rated compared to the previous year), vitality
(e.g. low energy), social functions (e.g. whether physical or
emotional problems would influence contact with friends),
role emotional (e.g. whether there are problems at work due
to mental health problems) and mental health (e.g. being un-
happy). The score for each subscale ranges from 0 to 100, with
higher scores indicating better HRQoL. The eight subscales
can be summarized by two standardized component summary
scores, namely,, a physical component summary (PCS) score
and a mental component summary (MCS) score, with a mean
of 50 [standard deviation (SD)=10]. In this study, gender-
matched German-speaking members of the community rang-
ing in age from 30 to 49 years (mothers) and from 40 to
49 years (fathers), were used as controls to obtain the norma-
tive data (n=6964) [30, 31]. These age ranges correspond
approximately to the inter-quartile ranges (IQRs) of the study
participants’ ages. In the study sample, internal consistencies
of all subscales were satisfactory to excellent (Cronbach’s α
between 0.51 and 0.95) and good for the two summary com-
ponent scores (Cronbach’s α=0.89 for the mothers, both PCS
and MCS; Cronbach’s α=0.90 for the fathers, both PCS and
MCS).
Parental mental health
Self-reported mental health was measured with the authorized
German version of the Brief Symptom Inventory (BSI) [32, 33].
The BSI includes 53 items regarding the frequency of psycho-
logical distress symptoms during the past week. It consists of
nine scales: somatization, obsessive–compulsive, interpersonal
sensitivity, depression, anxiety, hostility, phobic anxiety, para-
noid ideation and psychoticism. In addition, the BSI provides an
overall measure of psychopathology, i.e., the Global Severity
Index. Higher scores indicate lower mental health. Gender-
matched T-scores (mean50, SD10) were derived based on nor-
mative data from a community sample of 600 healthy German
adults (300 females and 300 males) [33]. In our study, the in-
ternal consistency of the nine scales was found to be satisfactory
to good (Cronbach’s α between 0.57 and 0.85) and for the
Global Severity Index it was excellent (Cronbach’s α=0.95
for both mothers and fathers).
Parental PTSD
Posttraumatic stress disorder was assessed by the validated
German version of the Posttraumatic Diagnostic Scale
(PDS) [34–36], a diagnostic instrument which provides a
diagnosis of PTSD according to the criteria of the DSM-IV
[18] and a rating of PTSD symptom severity. The PDS
consists of four parts. The first part concerns the type of
traumatic event and, if there were multiple events, the most
stressful one. The second part evaluates the time, the cir-
cumstances and the emotions in the context of the trauma.
The third part assesses the frequency of 17 PTSD symp-
toms belonging to the three symptom clusters (i.e. intru-
sion, avoidance and hyperarousal) during the last month
before assessment on a four-point Likert scale (0–3), with
a symptom rated as present if the corresponding item has a
score of ≥1. The 17 items are summarized by a total symp-
tom severity score that ranges from 0 to 51, such that
higher scores indicate greater symptom severity (mild se-
verity, score ≤10; severe, score ≥36). The fourth part con-
cerns impairments in different areas of life (e.g. job). The
criteria for diagnosis of full PTSD were met if parents
reported at least one intrusion symptom, three avoidance
symptoms and two hyperarousal symptoms, as well as a
duration of these symptoms of at least 1 month and im-
paired function in at least one life area [18]. For the diag-
nosis of partial PTSD, parents had to report fewer symp-
toms for each symptom cluster (e.g. at least one avoidance
symptom compared to at least three avoidance symptoms
which were required for the diagnosis of full PTSD), while
the criteria for the duration of the symptoms and impaired
function were the same [36]. In this study, HUS-related
PTSD was analyzed in those parents who indicated that
their child’s HUS was the most stressful traumatic event.
In the sample of parents assessed in this study, the internal
consistency of the HUS-related PTSD symptom severity
score was good (for the mothers: Cronbach’s α= 0.83; for
the fathers Cronbach’s α= 0.84).
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Socioeconomic status
Socioeconomic status was assessed with a demographic ques-
tionnaire and estimated according to maternal education and
paternal occupation on a scale ranging from 2 to 12, with 2
being the lowest and 12 the highest SES score. Three social
classes were assigned: lower (SES scores 2–5), middle (SES
scores 6–9) and upper (SES scores 10–12). This measure has
been proven to be a valid indicator of SES in previous studies
involving the Swiss population [37].
Statistical analysis
Data were analyzed using the SPSS statistical package for
Windows version 22.0 (IBM Corp., New York, NY). All
tests were two-sided, and a p value of <0.05 was consid-
ered to be significant. Chi-square tests and Mann–Whit-
ney U tests were used as appropriate to compare child
sex, child age at HUS diagnosis, need for dialysis during
acute HUS, length of hospital stay, development of ESRD
and SES between participants and non-participants.
Cronbach’s alpha (α) was calculated to test the internal
reliability of scale scores. HRQoL and mental health dif-
ferences between the study sample and normative data
were examined using one-sample t tests. Because most
of the HRQoL and mental health scales as well as the
PTSD total symptom severity scale showed non-normal
distributions according to the Kolmogorov–Smirnov test,
we used Wilcoxon signed-rank tests for testing the equal-
ity of means between mothers and fathers. For all com-
parisons, effect sizes were computed with Cohen’s d
(small effect 0.20; medium effect 0.50; large effect
>0.80; study group vs. normative data; mothers vs. fa-
thers) [38]. Multiple linear regression models were used
to predict parental HRQoL using the MCS as the depen-
dent variable. Due to non-normal distribution of the resid-
uals, the MCS of the mothers and fathers was reflected
square-root transformed for the regression analysis [39],
which resulted in normally distributed residuals according
to regression plots (histograms of the standardized resid-
uals and probability plots). For both parents, two blocks
of predictors were entered into the regression analyses.
Block 1 (child medical characteristics) comprised type of
HUS (atypical vs. typical HUS), time since acute HUS
(years), dialysis during acute episode (yes vs. no), dura-
tion of hospital stay during acute episode (days) and
chronic kidney disease (yes vs. no). Block 2 (child
sociodemographic factors) comprised female sex, age at
assessment of parental data (years) and SES (upper vs.
middle/lower SES class). Selection of predictors was
based on their assumed clinical relevance for parental
HRQoL. The assumption of multi-colinearity was tested
by checking the correlation matrix for high correlation
coefficients (>0.80) and the variance inflation factor,
which was not violated [40].
Results
Sociodemographic characteristics of children and parents
At assessment of parental data, the 63 HUS-affected children
(56 % females) had an average age of 9.3 (SD4.6, median 9.6,
range 1.1–17.9) years. The mean age of the mothers and fa-
thers was 41.1 (SD6.3, median 41.5, IQR 36–46) years and
44.3 (SD6.7, media 45.0, IQR 40–48) years, respectively. The
SES of the participating families was categorized as lower
class (4 families, 6 %), middle class (43, 68 %) and upper
class (16, 26 %).
Diagnostic and medical characteristics of the children
Descriptive diagnostic and medical data of the HUS-affected
children are shown in Table 1. The mean time for the pediatric
patient group since an acute episode of HUS was 6.4 (SD4.4,
media 6.1, range 0.1–16.5) years. The predominant type of
HUS was STEC-HUS, with verification of Shiga toxin in 35
cases. Of the 53 children with STEC-HUS, 36 (68%) required
dialysis during the acute phase of HUS. P-HUS was diag-
nosed in seven children (11 %), of whom one had meningitis,
five had pneumonia and one had pneumonia and peritonitis;
five of these seven children required dialysis during the acute
phase of HUS. aHUS was diagnosed in three of the 63 chil-
dren (5 %), with one or more complement-related mutations
found in two of these three children. All three aHUS patients
required acute dialysis, with two of them additionally requir-
ing chronic dialysis.
Twenty-four of the patients (38 %) had CKD (18 with a
STEC-HUS episode, 3 with a P-HUS episode, and 3 with
aHUS). Most of these children were under medical supervi-
sion or required specific renal treatment. Of these 24 children,
five had ESRD, and four of these five children had already
undergone renal replacement (STEC-HUS, n= 1; P-HUS,
n=1; aHUS, n=2); one child with STEC-HUS was still on
the waiting list for preemptive renal replacement at the time of
assessment.
HUS-related long-term extrarenal sequelae were observed
in three of the 24 patients with CKD. There was one case each
of insulin-dependent diabetes mellitus due to STEC-HUS-
related pancreatitis; severe neurodevelopmental impairment
secondary to neurological involvement during acute STEC-
HUS; impaired visual acuity due to retinal bleeding during
acute STEC-HUS. In addition, three CKD patients were af-
fected by another chronic disease unrelated to HUS (e.g. tho-
racic lymphangioma, hearing disorder and complications due
to prematurity).
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Health-related quality of life
Mean values of the HRQoL scales of the mothers and fathers
and statistics for comparison of the study sample with norma-
tive data are presented in Table 2. For the mothers, all HRQoL
subscales and the two component summary scales (MCS and
PCS) were above the population norm, with the mothers of
HUS-affected children showing better HRQoL than the pop-
ulation sample. Among fathers, better HRQoL scores than for
male references were reported for physical function, role
limitations due to physical problems, bodily pain, general
health, emotional problems and PCS. For the other subscales
and the MCS, paternal HRQoL was comparable to the norma-
tive data. Differences between the study sample and norma-
tive data were found with medium effect sizes for both
mothers and fathers with respect to bodily pain, general health
and PCS. Significant differences between mothers and fathers
with small effect sizes were only found for role limitations
caused by physical problems, which were less common in
the fathers.
Prediction of parental HRQoL by HUS-related
and sociodemographic characteristics
The statistics for the block-wise multiple regression analyses
predicting parental HRQoL (MCS) are summarized in Table
3. Among mothers and fathers, the overall statistical model
was not significant, accounting for 16 % of the total variance
in mothers and 14% in fathers. Maternal and paternal HRQoL
did not differ with respect to their child’s HUS type (aHUS, P-
HUS, STEC-HUS). However, a shorter time since the child
suffered an acute episode of HUS was a significant predictor
of lower maternal HRQoL (MCS; the negative relationship
between MCS and the time since diagnosis is valid for the
transformed MCS, while for the original variable the relation-
ship is positive). This effect was not present for the fathers.
Mental health
Mean values of maternal and paternal mental health scales
and statistics for comparisons of the study sample with
normative data are presented in Table 4. Statistical analy-
ses revealed fewer psychopathological symptoms with
small effect sizes in the parents than in normative data
with respect to the Global Severity Index. Furthermore,
both parents reported significantly fewer obsessive–com-
pulsive symptoms, interpersonal sensitivity and less anx-
iety than gender-matched norms. In contrast to the fathers,
mothers also reported significantly fewer symptoms of
depression and phobic anxiety than female references.
Differences between mothers and fathers with small effect
sizes were found for depression and phobic anxiety, with
fathers reporting more problems.
Prediction of parental mental health
The overall statistical model was not significant for mothers
and fathers, accounting for 9% of the total variance inmothers
and 11 % in fathers. None of the selected predictors for lower
parental mental health (Global Severity Index for mothers and
fathers) was significant.
Table 1 Diagnostic and medical characteristics of children with
hemolytic uremic syndrome(n= 63)
Diagnostic and medical characteristics Values
Classification of HUS type
STEC-HUS 53 (84 %)
P-HUS 7 (11 %)
aHUS 3 (5 %)
Data on acute episode of HUS
Child age at diagnosis (years) 3.0 ± 3.1
Time since acute HUS (years) 6.4 ± 4.4
Dialysis 44 (70 %)
Peritoneal dialysis 33 (75 %)
Hemofiltration/Hemodialysis 7 (16 %)
Combination of peritoneal dialysis and
hemofiltration/hemodialysis
4 (9 %)
Duration of dialysis (days) 10.6 ± 14.5 [0–79]
On dialysis at time of discharge 2 (3 %)
Stay in intensive care unit 57 (91 %)
Duration of stay in intensive care unit (days) 7.81 ± 6.8 [0–31]
Duration of hospital stay (days) 23.7 ± 17.4 [5–97]
Clinical course of HUS at time of assessment
Chronic kidney disease 24 (38 %)
Stage 1 9 (38 %)
Stage 2 10 (42 %)
Stage 3 0 (0 %)
Stage 4 0 (0 %)
Stage 5 5 (20 %)
Treatment modalities of the chronic
kidney disease patients
Conservative medical treatment 8 (33 %)
Plasmapheresis (and conservative
treatment)
1 (4 %)
Renal transplantation 4 (17 %)
Medical supervision 11 (46 %)
HUS-related long-term extrarenal sequelae, 3 (5 %)
Data are presented as the mean ± standard deviation (SD), with/without
the range in square brackets, or as a number with the percentage in
parenthesis
HUS, Hemolytic uremic syndrome; STEC-HUS, Shigatoxin-associated
HUS; P-HUS, Streptococcus pneumoniae-associated HUS; aHUS, atyp-
ical HUS
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Table 2 Health-related quality of life of mothers and fathers with HUS-affected children, compared with population norm and between mothers and
fathers
SF-36 scales Mothers (n= 61–63) Comparison of mothers’
HRQoL with female
references (normative data)a
Fathers (n= 58) Comparison of fathers’
HRQoL with male references
(normative data)a
Comparison of mothers’
and fathers’ HRQoLb
(n= 56 –58)
p dc, d p d c, d p d c, e
Physical functions 94.4 ± 16.5 0.02 0.30 96.2 ± 8.0 <0.001 0.44 0.88 −0.14
Role physical 91.1 ± 20.9 0.01 0.27 97.4 ± 10.1 <0.001 0.46 0.04 −0.38
Bodily pain 83.8 ± 22.0 <0.001 0.77 90.0 ± 16.6 <0.001 0.88 0.09 −0.32
General health 80.8 ± 16.1 <0.001 0.69 77.6 ± 16.1 <0.001 0.59 0.30 0.20
Vitality 65.7 ± 17.1 <0.001 0.48 67.1 ± 17.2 0.20 0.17 0.73 −0.08
Social functions 89.3 ± 18.5 0.05 0.24 90.7 ± 15.6 0.46 0.09 0.49 −0.08
Role emotional 94.5 ± 20.4 <0.01 0.30 96.0 ± 15.4 0.05 0.20 0.52 −0.08
Mental health 77.4 ± 14.9 <0.001 0.47 76.7 ± 15.9 0.48 0.10 0.82 0.04
PCS 54.3 ± 7.6 <0.001 0.70 55.4 ± 4.7 <0.001 0.81 0.70 −0.18
MCS 52.1 ± 8.8 <0.01 0.34 51.6 ± 8.2 0.85 −0.02 0.78 0.06
Data on health-related quality of life (HRQoL) are presented as the mean ± SD. The higher the value, the better the HRQoL
SF-36, Medical Outcomes Study Short Form-36 item questionnaire; PCS physical component summary score of SF-36; MCS, mental component
summary score of SF-36
aValues are presented as the mean ± SD. One-sample t tests were performed
bWilcoxon signed-rank tests were performed
c d=Effect size according to Cohen [38], with a Cronbach’sα value of 0.20 indicating a small effect; anα value of 0.50 indicating amedium-sized effect;
an α value of >80 indicating a large effect)
d Differences: Study sample vs. normative data (positive d indicates better HRQoL for the study sample compared to the population norm)
e Differences: Mothers’ vs. fathers’ data (positive d indicates better HRQoL for the mothers than for the fathers)
Table 3 Prediction of parental
health-related quality of lifea by
multiple regression analysis of the
medical and sociodemographic
characteristics of the HUS-
affected child (n= 61)
Medical and sociodemographic characteristics Mothers (n = 61) Fathers (n= 58)
Δ R2 ß Δ R2 ß
Block 1: Medical characteristics 0.074 0.089
Atypical HUS −0.03 0.05
Time since acute HUS −0.44* 0.20
Dialysis during acute episode −0.18 −0.08
Duration of hospital stay during acute episode 0.02 −0.28
Chronic kidney disease 0.12 0.19
Block 2: Sociodemographic characteristics 0.087
Female sex 0.15 0.21
Age at assessment 0.29 0.04
Upper SES class 0.13 0.07
Total R2 0.161 0.137
Total R2 adjusted 0.032 −0.004
*p ≤ 0.05, ** p ≤0 .01, *** p ≤0.001
ΔR2 , Change in multiple regression coefficient; β standardized regression coefficient; SES socioeconomic status
a Health-related quality of life (HRQoL) assessment was based on the mental component summary (MCS) score
of the SF-36, where theMCS score is one of two standardized component summary scores of the SF-36. For both
mothers and fathers MCSwas transformed. For interpretation, the direction of ß has to be reversed; for actual use
of the regression equation, the transformed MCS has to be backtransformed
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Posttraumatic stress disorder
Overall, 48 of the 63 mothers (76 %) and 41 of the 58 fathers
(71%) reported some traumatic experience, and the criteria for
full PTSD (due to any traumatic events) were met by three
mothers (5 %) and two fathers (3 %). The HUS of their re-
spective child was stated as a single and/or the most troubling
traumatic experience by 24 of the 48 mothers (50 %) and by
20 of the 41 fathers (49 %). Descriptive information with
respect to the number of HUS-related PTSD symptoms and
the HUS-related symptom severity scales is given in Table 5.
None of the mothers (0 %) met the criteria for full HUS-
related PTSD, while four mothers (6 %) met the criteria for
partial HUS-related PTSD. Among the fathers, one (2 %) and
two fathers (4 %) met the criteria for partial HUS-related
PTSD and full HUS-related PTSD, respectively.
Discussion
This cross-sectional study provides a comprehensive insight
into self-reported HRQoL and mental health in relation to
PTSD symptoms in parents of HUS-affected children. Our
results show that neither HRQoL nor mental health was im-
paired in the mothers or the fathers of our study sample com-
pared to normative data, while full HUS-related PTSD was
diagnosed in two fathers but no mothers.
In contrast to our hypothesis, parental HRQoL was com-
parable with or even greater than the population norm. This
result is consistent wit those from a number of previously
published studies on HRQoL in parents of children with other
life-threatening or chronic diseases (e.g. meningococcal septic
shock [23], Kawasaki syndrome [24] or juvenile iodiopathic
arthritis [41]). However, it differs from the finding of one
study of parents of children with ESRD where the parents
had a lower HRQoL than healthy references (e.g., with respect
to depressive symptoms and vitality) [13]. The findings of a
study on parents of children with advanced CKD also differ
from our results [14]. One possible explanation for our results
is the small number of children with ESRD or advanced CKD.
Furthermore, methodological differences between the avail-
able studies with parents of pediatric HUS patients (e.g. the
use of different HRQoL questionnaires) make it difficult to
compare the results. However, the greatest differences in
HRQoL (medium effect sizes) between the study sample and
the population norm were found for maternal and paternal
bodily pain, general health and the PCS. We can therefore
speculate that parents of HUS-affected children rate their
own physical health as better than the norms because they rate
their health in comparison to that of their sick child. Our study
also indicated that a shorter time since an acute episode of
HUS was a significant predictor of lower maternal HRQoL,
which is consistent with previous studies of parents with chil-
dren having other chronic diseases (e.g., heart disease) and
also with a phase model of adjustment of medical stress as
Table 4 Mental health of mothers and fathers with HUS-affected children, compared with population norm and between mothers and fathers
Brief Symptom
Inventory scales
Mothers (n= 63) Comparison of mothers’
mental health scores with
normative dataa
Fathers (n= 58) Comparison of fathers’
mental health scores with
normative datab
Comparison of mothers’
and fathers’ mental health
scoresb
p d c, d p d c, d p d c, e
Somatization 47.8 ± 8.9 0.05 −0.23 48.0 ± 9.3 0.10 −0.21 0.79 −0.02
Obsessive-compulsive 46.6 ± 10.4 0.01 −0.33 46.9 ± 10.4 0.03 −0.30 0.37 −0.03
Interpersonal sensitivity 46.7 ± 10.8 0.02 −0.32 47.6 ± 8.5 0.04 −0.26 0.43 −0.09
Depression 46.6 ± 9.7 <0.01 −0.35 49.3 ± 8.9 0.53 −0.08 0.01 −0.29
Anxiety 47.4 ± 10.0 0.05 −0.26 47.3 ± 9.8 0.04 −0.27 0.68 0.02
Hostility 49.3 ± 10.7 0.58 −0.07 49.5 ± 9.5 0.70 −0.05 0.87 −0.03
Phobic anxiety 47.4 ± 7.4 <0.01 −0.30 48.4 ± 7.4 0.11 −0.18 <0.001 −0.14
Paranoid ideation 48.1 ± 9.4 0.12 −0.19 50.5 ± 9.9 0.71 0.05 0.06 −0.24
Psychoticism 50.8 ± 10.2 0.55 0.08 48.2 ± 7.8 0.08 −0.20 0.50 0.29
Global Severity Index 45.0 ± 13.2 <0.01 −0.43 45.0 ± 13.5 <0.01 −0.42 0.96 −0.01
Data on the mental health of the parents are presented as the mean ± SD. The higher the value, the lower the mental health score
aWilcoxon signed-rank tests were performed
bOne-sample t tests were performed
c d=Effect size according to Cohen [38], with a Cronbach’sα value of 0.20 indicating a small effect; anα value of 0.50 indicating amedium-sized effect;
an α value of >80 indicating a large effect)
d Differences: study sample vs. normative data (negative d indicates better mental health for the study sample compared to the population norm)
e Differences: Mothers’ vs. fathers’ data (negative d indicates better mental health for the mothers than for the fathers)
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suggested by Kazak et al. [42, 43]. This model describes three
consecutive phases of traumatic stress responses to medical
events, with increasing traumatic stress during phase I (also
called Peri-Trauma which includes the initial traumatic event
and surrounding events as, for example, invasive medical
procedures).
In our study, maternal and paternal mental health as
measured by the BSI was not impaired compared to nor-
mative data. This is in contrast to previous reports on the
psychological distress of parents with children affected by
HUS assoc ia t ed wi th ve rocy to tox in -p roduc ing
Escherichia coli [17] and by various chronic diseases
[12, 44]. However, in our study only 24 of the 63 children
(38 %) had CKD, which might partly explain our result.
Furthermore, we found no significant association between
HUS-related or sociodemographic characteristics and pa-
rental mental health in our study. Our finding might be
also explained by a so-called response shift [45], such that
parents might have adapted to the new situation over time
and are therefore satisfied with less compared to the nor-
mal population. It might also be that parents of the HUS-
affected children received good medical care and adequate
social support, which possibly might have mitigated pa-
rental distress. Another possibility is that parents might
experience personal growth in relation to their child’s
HUS and the difficulties associated with it [46, 47]. How-
ever, we found that some parents—even 6.4 years after
the acute HUS episode—were affected by full or partial
PTSD due to their child’s HUS. In fact, it is possible that
parents simply do not report mental health problems as
measured by the BSI and the presence of PTSD symp-
toms. The BSI does not ask about such symptoms. Our
finding should be of great interest to nephrologists and
other healthcare providers caring for HUS-affected chil-
dren and their families during the clinical follow-up.
Assessing and treating any posttraumatic stress symptoms
in these parents may prevent or at least mitigate any neg-
ative consequences of PTSD and may also help maintain
their competency as caregivers [48].
This study is the first to report HRQoL and mental health
data of parents with HUS-affected children. Its strengths in-
clude the use of standardized multidimensional questionnaires
and the comparison of results with normative data. Further-
more, a high proportion of fathers (92 % of participating fam-
ilies) participated in our study, allowing comparisons between
maternal and paternal HRQoL and mental health scales. Nev-
ertheless, our study has several limitations. First, our study
sample comprised different HUS types characterized by some
heterogeneity with respect to HUS etiology, pathophysiology
and the clinical course of the disease. Thus, while we were
Table 5 Prevalence of post-traumatic stress symptoms and post-traumatic stress disorder (PTSD) according to DSM-IV in 63 mothers and 58 fathers
experiencing their child’s hemolytic uremic syndrome (HUS) as a traumatic event
Posttraumatic Diagnostic Scale items Mothers Fathers Comparison between mothers and fathersa
p db
Parents stating their child’s HUS as a traumatic event 24 (38 %) 20 (35 %)
Intrusion
DSM-IV criterion met 20 (32 %) 10 (17 %)
Number of symptoms 2.1 ± 1.5 [0–5] 1.2 ± 1.4 [0−4] 0.02 0.65
Avoidance
DSM-IV criterion met 1 (2 %) 2 (4)
Number of symptoms 0.9 ± 1.4 [0–6] 0.6 ± 1.3 [0–5] 0.02 0.24
Hyperarousal
DSM-IV criterion met 7 (11 %) 6 (10 %)
Number of symptoms 1.1 ± 1.5 [0–5] 0.9 ± 1.2 [0–3] 0.11 0.17
All 3 symptom clusters
DSM-IV criteria for full PTSD met 0 (0 %) 2 (4)
Criteria for partial PTSD met 4 (6 %) 1 (2)
Total symptom severity 6.1 ± 6.7 [1–30] 3.1 ± 4.0 [0–15] <0.01 0.54
Data are presented as the mean ± SD with the range given in square brackets, or as a number with the percentage in parenthesis
PTSD, Post-traumatic stress disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (version IV)
aWilcoxon signed-rank tests for continuous variables were performed
b d=Effect size according to Cohen [38], with a Cronbach’sα value of 0.20 indicating a small effect; anα value of 0.50 indicating amedium-sized effect;
an α value of >80 indicating a large effect). Mothers’ vs. fathers’ data, with a positive d indicating a higher number of PTSD symptoms for the mothers
than for the fathers
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able to present a good overview of the broad clinical HUS
spectrum, our study included a rather small number of chil-
dren with aHUS, making it difficult to compare parental
HRQoL and mental health issues with respect to the type of
pediatric HUS. However, our multivariate regression analysis
revealed that the type of HUS was not a significant predictor
for parental HRQoL. Secondly, our data were compared with
gender-matched normative data that might be more or less
than sufficient. We compared our data with normative data
within the same inter-quartile age ranges, but not with exactly
age-matched controls. Since it is well known that age has an
influence on HRQoL and mental health changes [30], this
methodological issue might have influenced our results. How-
ever, our study provides a good insight into the issues which
are most strongly affected and which should be carefully con-
sidered in clinical practice.
In conclusion, the results of our study indicate that HRQoL
and mental health in parents of children with a history of HUS
were comparable with or better than normative data. However,
a few parents of our study sample suffered from full or partial
PTSD due to their child’s HUS. Although the prevalence of
HUS-related PTSD was small, special attention should be
given to parental PTSD symptoms in the clinical follow-up
of HUS-affected children, since even partial PTSD might lead
to functional impairment [36] and some parents would prob-
ably benefit from psychological support.
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Abstract
Background: Membranoproliferative glomerulonephritis (MPGN) with immune complexes and C3 glomerulopathy (C3G) in
children are rare and have a variable outcome, with some patients progressing to end-stage renal disease (ESRD). Mutations
in genes encoding regulatory proteins of the alternative complement pathway and of complement C3 (C3) have been
identified as concausative factors.
Methods: Three children with MPGN type I, four with C3G, i.e. three with C3 glomerulonephritis (C3GN) and one with dense
deposit disease (DDD), were followed. Clinical, autoimmune data, histological characteristics, estimated glomerular
filtration rate (eGFR), proteinuria, serum C3, genetic and biochemical analysis were assessed.
Results: The median age at onset was 7.3 years and the median eGFR was 72 mL/min/1.73 m2. Six children had marked
proteinuria. All were treated with renin–angiotensin–aldosterone system (RAAS) blockers. Three were given one or more
immunosuppressive drugs and two eculizumab. At the last median follow-up of 9 years after diagnosis, three children had
normal eGFR and no or mild proteinuria on RAAS blockers only. Among four patients without remission of proteinuria,
genetic analysis revealed mutations in complement regulator proteins of the alternative pathway. None of the three
patients with immunosuppressive treatment achieved partial or complete remission of proteinuria and two progressed to
ESRD and renal transplantation. Two patients treated with eculizumab revealed relevant decreases in proteinuria.
Received: 31.8.2017. Editorial decision: 27.12.2017
VC The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
1
Clinical Kidney Journal, 2018, 1–12
doi: 10.1093/ckj/sfy006
Original Article
Conclusions: In children with MPGN type I and C3G, the outcomes of renal function and response to treatment modality
show great variability independent from histological diagnosis at disease onset. In case of severe clinical presentation at
disease onset, early genetic and biochemical analysis of the alternative pathway dysregulation is recommended. Treatment
with eculizumab appears to be an option to slow disease progression in single cases.
Key words: C3 glomerulopathy, complement dysregulation, eculizumab, MPGN, paediatrics
Introduction
Membranoproliferative glomerulonephritis (MPGN) with
immune complexes is a rare chronic glomerulonephritis in
childhood characterized by proteinuria (up to the nephrotic
range), haematuria, hypertension and often impaired renal
function at disease onset [1]. In up to 50% of affected children,
MPGN leads to renal failure within 10 years [2]. Impaired renal
function after 1 year of onset is considered a risk factor for poor
renal outcome and end-stage renal disease (ESRD) [1]. The
recurrence rate after renal transplantation (RTPL) is high (up to
45%) [1–4]. MPGN may occur as a primary genetic disorder or
secondary to chronic diseases, including infections (e.g. hepati-
tis B or C), systemic lupus erythematosus, liver disease and
malignancies.
In the past, MPGN was diagnosed and classified by renal his-
tological features and grouped into three pathological subtypes
with different aetiologies and pathogenesis, types I, II [(dense
deposit disease (DDD)] and III [5]. Activation of the alternative
complement pathway has repeatedly been observed in conjunc-
tion with low serum levels of complement C3 (C3) [6–8]. A link
between dysregulation of the alternative complement pathway
and the pathogenesis of MPGN was assumed [7] and has
recently been confirmed by findings of mutations in the genes
of complement factor H (CFH) and CF-related proteins (CFHR) in
DDD [9–13].
Therefore the histological classification has been reconsid-
ered recently on the basis of pathogenesis and with division
into those cases in which the glomerular immune deposits stain
for immunoglobulins and complement and those cases that are
characterized by C3 deposition alone [5, 14–16]. The term ‘C3
glomerulopathy’ (C3G) encompassed complement-mediated
renal disease, and therefore incorporates disease entities where
the presence of a disease-associated complement mutation is
causally associated with the underlying renal pathology.
Examples include DDD and C3 glomerulonephritis (C3GN) [5].
The term C3GN was coined to describe glomerular lesions in
which there is glomerular accumulation of C3 with little or no
immunoglobulin in the absence of the characteristic highly
electron-dense transformation seen in DDD [16]. The incidence
of C3G is estimated to be 1–2 per 106 children [17, 18], with dis-
ease recurrence after RTPL reported at between 30 and 77% and
a graft failure due to recurrence in 17–50% of the recipients
[19, 20]. MPGN associated with the presence of immunoglobu-
lins and complement has been termed immune complex–medi-
ated MPGN by Sethi and Fervenza [21]. Immune complex-
mediated MPGN is commonly associated with autoimmune dis-
ease and chronic infection and can be associated with mixed
cryoglobulinaemia or monoclonal gammopathy [5, 21]. These
associations were excluded in our study. In our series, histologi-
cal MPGN I is a case of so-called idiopathic MPGN. MPGN I and
C3G are regarded as heterogeneous diseases, with several stud-
ies reporting complement mutations in complement genes [15,
22]. So far there are no evidence-based guidelines for treatment
of MPGN I [1, 2] and C3G. The mainstay of treatment in MPGN I
and C3G is based on single-centre studies and expert opinions.
Clinical trials in adults and children with different treatment
modality propositions [e.g. immunosuppressant agents, anti-
platelet drugs and plasmapheresis (PEX)] are described [23–29].
Treatment with renin–angiotensin–aldosterone system (RAAS)
blockers are described to induce a decrease in proteinuria and
delays progression to ESRD in many glomerular diseases in
adults [30, 31] and in some glomerulopathies in children [32, 33];
however, there is no evidence for beneficial effect in children
with MPGN I [34] and spontaneous recovery in C3GN can also
not be excluded [22].
Eculizumab is a monoclonal antibody binding to C5 and
thereby inhibiting the complement system and preventing acti-
vation of the alternative pathway. Recently, promising results
were shown in selected patients with MPGN and C3GN charac-
terized by the presence of alterations in regulatory proteins of
the alternative complement pathway [22, 35–37].
We evaluated the outcome of seven children with the diag-
nosis of MPGN I, C3GN and DDD. All were screened for the pres-
ence of genetic mutations of the alternative complement
pathway. We analysed the benefit of different administered
treatments.
Materials and methods
All patients with histologically diagnosed MPGN I, DDD and
C3GN who were seen at the University Children’s Hospital
Zurich between 2003 and 2015 were included in a retrospective
data analysis. Clinical assessment included diagnosis, sex, med-
ical history, clinical examination, blood pressure (BP) and analy-
sis to exclude potentially secondary forms of MPGN.
Biochemical and genetic analysis
Plasma creatinine, total serum protein and albumin and urinary
protein:creatinine ratio (UPCR) were analysed at disease onset
and at the last follow-up. Blood samples for complement regu-
lator protein analysis were centrifuged immediately after col-
lection and frozen at80C prior to analysis. C3 serum levels
were evaluated by kinetic nephelometry (Immage 800, Beckman
Coulter, Brea, CA, USA) with a normal value>0.7 g/L (reference
value of the immunology laboratory of Zurich University
Children’s Hospital). The soluble complement components C5b-
9 (membrane attack complex), C3d and C3 nephritic factor
(C3NeF) were measured from plasma samples at the Institute
for Immunology of Heidelberg University (Heidelberg,
Germany). The following biochemical analyses were performed
at follow-up from plasma and serum, as well as ethylenediami-
netetraacetic acid blood samples for genetic analysis (samples
at the Leibniz Institute for Natural Product Research and
Infection Biology, Jena, Germany): CFH antibody, C3-convertase
antibody, CFI, CFB, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, MCP
(CD46) and by next-generation sequencing (NGS) at the Center
for Human Genetics at Bioscientia in Ingelheim (Germany), as
described in detail below.
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Targeted NGS using a customized multigene panel for atypi-
cal hemolytic uremic syndrome (aHUS) and related disorders
was performed in all patients [38]. In brief, we utilized a custom-
ized sequence capture library that targets exons and addition-
ally 35 bp of flanking intronic sequence (20–23). Genomic DNA
was fragmented and the coding exons of the analysed genes, as
well as the corresponding exon–intron boundaries, were
enriched using the Roche/NimbleGen sequence capture
approach (NimbleGen, Madison, WI, USA), amplified and
sequenced simultaneously by Illumina NGS sequencing-by-
synthesis technology using a HiSeq 1500 system (Illumina, San
Diego, CA, USA). Target regions were usually sequenced with an
average coverage of  400–500-fold. With this method, 20-fold
coverage is obtained for >99.5% of the regions of interest. NGS
data analysis was performed using bioinformatic analysis tools
and JSI Medical Systems software (version 4.1.2; JSI Medical
Systems, Kippenheim, Germany). Identified variants and indels
were filtered against external and internal databases and
depending on allelic frequency. The focus was on rare variants
with a minor allele frequency of 1%. Nonsense, frameshift
and canonical splice site variants were considered a priori as
likely to be pathogenic. Pathogenicity of identified non-
synonymous variants was assessed using bioinformatic predic-
tion programs, such as Mutation Taster, Polyphen-2,
MutationAssessor and FATHMM. Only those variants predicted
by the majority of algorithms used to be probably damaging
were considered likely to be pathogenic. In silico analysis of
splice site effects was performed using bioinformatic programs
such as Fruitfly, NetGene2, Human Splicing Finder, Mutation
Taster and ESEFinder. Mapping and coverage statistics were
generated from the mapping output files using GATK. The
resulting sequence data were compared with the reference
sequence of the RefSeq database. High coverage enabled copy
number variation analysis. Potential copy number alterations
were initially identified by VarScan on mapped reads. In this
way, coverage of every target region of the sample was inter-
nally normalized and compared with normalized control data
of other samples of the same run by VarScan copy number
mode and standard settings. Putative pathogenic differences
between the wild-type sequence (human reference genome
according to the University of California, Santa Cruz Genome
Browser: hg19, GRCh37) and the patient’s sequence were vali-
dated by conventional Sanger sequencing and, in the case of
copy number variation, by multiplex ligation-dependent probe
amplification.
Renal biopsy
All patients underwent native kidney biopsy at disease onset.
Repeated renal biopsy was performed in two children, one of
the native kidneys and one in the transplanted kidney. The
biopsy diagnosis was based on the current classification and
nomenclature for C3G and MPGN [5, 16] on findings by light
microscopy (LM), immunofluorescence (IF) and electron micro-
scopy (EM).
Definitions
The following definitions were used: nephrotic-range proteinuria:
UPCR >250 g/mol; nephrotic syndrome: serum albumin<25 g/L,
nephrotic-range proteinuria and generalized oedema; remission:
UPCR <20 g/mol; partial remission: UPCR >20–<80 g/mol; normal
renal function: estimated glomerular filtration rate
(eGFR)>90 mL/min/1.73 m2, as calculated by the Schwartz
formula using a local k-factor of 40 [39]; hypertension: casual sys-
tolic BP>95th percentile for sex and height [40].
Treatment
All patients were given RAAS blockers as first-line antiproteinu-
ric therapy. Additional treatment consisted of prednisolone
(PDN), in accordance with the dosage regimen for treatment of
children with steroid-resistant nephrotic syndrome [41, 42].
Further immunosuppressive treatment [cyclosporine A (CSA)
and mycofenolate mofetile (MMF)] [25, 42] was administered to
patients who failed to attain partial or full remission of protei-
nuria. Eculizumab has been available in our hospital since 2013,
but costs were not covered by all insurances, as this drug is still
off-label for MPGN/C3G treatment. Eculizumab was given to two
patients with nephrotic-range proteinuria despite immunosup-
pressive and RAAS blocker treatment. The dosage followed cur-
rent recommendations for aHUS [43]. Patients treated with
eculizumab were immunized with meningococcal vaccine
(Menveo, GlaxoSmithKline Biologicals, Rixensart, Belgium)
4 weeks prior to administration. Informed consent was obtained
from all parents of included patients for medical data collection,
genetic analysis and treatment with eculizumab.
Results
Seven children (four boys and three girls) fulfilled the inclusion
criteria (Table 1): three patients suffered from MPGN I, three from
C3GN and one from DDD. The median age at onset was 7.3 years
(range 2.5–12.5) with a median eGFR of 72 mL/min/1.73 m2 (range
41–140) at diagnosis.
Table 1. Patient characteristics at disease onset
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age (years) 7.3 2.5 6 12.5 5.9 10.5 8.8
Sex Male Male Female Female Male Female Male
Hypertension No No No No No Yes Yes
Haematuria Micro Micro Macro Micro Macro Micro Micro
UPCR (g/mol) (reference <20) 634 126 530 855 580 1500 1000
Nephrotic syndrome (UPCR >250 g/mol) No No No Yes No Yes Yes
Serum albumin (g/L) (reference 35–51) 27 32 26 11 30 12 12
eGFR (mL/min/1.73 m2) (reference >90) 72 140 41 67 88 65 95
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Analysis of the alternative complement pathway: CFs
and genetic testing
All children showed persistently low serum C3 (Table 2). In
addition, C3NeF was negative in all but one patient and C3b
antibodies were positive in two children with C3GN.
At the last follow-up (Tables 3–5), C3d was elevated in five
patients and sC5b-9 levels were increased in four children, both
in MPGN I and C3GN.
Renal biopsy
Renal biopsy findings (MPGN I, C3GN and DDD) (Figures 1–4) are
presented in Table 2. Repeated renal biopsy was performed in
Patient 4 (native kidney, before embarking on MMF) and Patient
7 (renal graft for suspected acute graft rejection). The diagnoses
were made based on IF findings. As the IF slides were no longer
available, the figures contain pictures of immunohistochemis-
try performed for the purpose of the publication.
Treatment regimens and follow-up
The median follow-up was 9 years (range 2.2–11.5). Five children
maintained renal function of their native kidneys, with a
median eGFR of 107 mL/min/1.73 m2 (range 40–180), including
four patients with normal eGFR. Two children reached ESRD
and underwent RTPL with initially good renal graft function. All
children had BP < 95th percentile, with six on RAAS blockers: in
one child, RAAS blockers were stopped after RTPL. All children
exhibited persistent haematuria. Three patients with nephrotic
syndrome (Patients 4, 6 and 7) exhibited progression of
proteinuria on PDN and were given additional immunosuppres-
sive treatment.
Patients with RAAS blockers only
Patients 1–3 (MPGN I, n52; C3GN, n51) (Table 3). All had nor-
mal renal function at onset without signs of a nephrotic syn-
drome. Follow-up was uneventful, with partial or complete
remission of proteinuria and maintained normal renal function.
All had persistently low C3. Genetic testing revealed a risk hap-
lotype for the membrane cofactor protein (MCP/CD46) gene in
all three children. In addition, Patient 2 (MPGN I) had elevated
sC5b-9 and a heterozygous mutation in the CFHR5 gene.
Patients with additional immunosuppressive
treatments, including eculizumab
Patient 4 (MPGN I) (Tables 4). Because of progressive proteinuria
on PDN, MMF was started [25]. Daily proteinuria initially
decreased from 4 to 2 g. However, impaired renal function and
nephrotic-range proteinuria persisted with elevated alternative
pathway activity. A second renal biopsy confirmed the diagno-
sis of MPGN I. Therefore MMF was discontinued and eculizumab
was started. Six months after starting eculizumab, a significant
decrease in proteinuria and sC5b-9 was observed with stabiliza-
tion of eGRF.
Patient 5 (C3GN) (Tables 4). Because of increasing proteinuria
with normal renal function and persistently elevated alterna-
tive pathway activity despite RAAS blockade, the treatment
Fig. 1. DDD native kidney (Patient 7). (A) Glomeruli with mesangial and endocapillary proliferation and a fibrocellular crescent [hematoxylin and eosin (H&E) stain, orig-
inal magnification 200]. (B) Intramembranous and mesangial deposits (acid fuchsin orange G stain, original magnification 200). (C and D) EM with highly osmiophilic
electron-dense deposits in the lamina densa of the glomerular basement membrane and mesangium (original magnification 1100 and 1950).
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with eculizumab was initiated [43]. After 11 months, proteinuria
and sC5b-9 level decreased, whereas C3NeF remained positive.
Renal function remained stable at a normal level.
Patient 6 (C3GN) (Table 5). Nephrotic-range proteinuria per-
sisted despite additional treatment with CSA for 6 years. The
child reached ESRD and underwent peritoneal dialysis 6.5 years
after disease onset. Deceased-donor RTPL was performed;
immunosuppression included tacrolimus, MMF, PDN and induc-
tion therapy with basiliximab. RAAS blocker was stopped.
Seven months after transplantation, sC5b-9 was still slightly
elevated. Renal graft function remained stable without
proteinuria.
Patient 7 (DDD) (Table 5). Additional treatment with CSA was
started due to persistent nephrotic-range proteinuria. The child
reached ESRD 4.2 years after disease onset. Living paternal-donor
RTPL was performed; immunosuppression included CSA, MMF
and PDN. The child experienced acute/active antibody-mediated
rejection (aABMR) and recurrence of DDD in the graft 3.3 years
Fig. 2. DDD recurrence in transplant biopsy (Patient 7). (A) Thickened, glassy GBM and endocapillary hypercellularity with mononuclear cells (H&E stain, original mag-
nification 200). (B) Intramembranous deposits and endocapillary proliferation (AFOG stain, original magnification 324). (C) Immunohistochemistry positive for C3
(original magnification 200). (D) Immunohistochemistry negative for immunoglobulin G (original magnification 200). (E and F) EM with highly osmiophilic electron-
dense deposits in the lamina densa and subepithelial humps (original magnification 1000 and 2500).
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after transplantation Therefore treatment with CSA was switched
to tacrolimus and PEX was started [1.5-fold plasma volume
exchange with fresh frozen plasma (FFP)], but ESRD occurred
3.9 years after RTPL. A deceased-donor RTPL was then performed.
Immunosuppression included tacrolimus, MMF, PDN and induc-
tion with thymeoglobulin. Again, ABMR and recurrence of the dis-
ease with nephrotic proteinuria occurred 15 months after
retransplantation. Weekly treatment with PEX reduced proteinu-
ria, but proteinuria increased when the PEX interval was extended
to every second week. Measurement of sC5b-9 (after PEX session)
showed normal values. Renal graft function was impaired (eGFR
42 mL/min/1.73 m2) at the last follow-up.
Discussion
MPGN and C3G are rare diseases with chronic progressive glo-
merulonephritis and children may have an unfavourable course
leading to ESRD [17, 18, 44, 45]. Studies in adults and children
have shown that proteinuria is a major risk factor for develop-
ing ESRD [1, 46, 47]. In the last decade, new insights are
Fig. 3. MPGN I (Patient 1). (A) Mesangial and endocapillary proliferation (periodic acid–Schiff stain, original magnification 110). (B) Splitting of the GBM (silver methen-
amine stain, original magnification 220). (C) Subendothelial deposits (AFOG stain, original magnification 200). (D) Immunhistochemistry positive for IgG (original
magnification 280), inset: positivity for C3 (original magnification 220). (E) EM with mostly subendothelial and some subepithelial and mesangial electron-dense
deposits (original magnification 1950). (F) Subendothelial and small subepithelial electron-dense deposits (original magnification 10 500).
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emerging to improve genetic and biochemical investigations of
these diseases.
Currently there is no established treatment for MPGN and C3G.
Patients appear to respond differently to various therapy modal-
ities [27, 29, 48, 49]. The majority of treatment regimens and case
series have been reported in adults, not in children [23, 26], and are
often associated with significant side effects. Recently, treatment
with eculizumab, a monoclonal antibody binding to C5 of the
alternative pathway, has shown promising results in the treatment
of some cases of MPGN and C3G [22, 35–37, 50].
Our analysis revealed a dysregulation of the complement
alternative pathway and mutation/variation in genes of CF pro-
teins in children with MPGN, C3GN and DDD. Three patients of
our series showed a favourable outcome. These were two
patients with MPGN I and one with C3GN, the latter without any
genetic variation in CFHR proteins. Five of seven children had a
Fig. 4. C3GN (Patient 6). (A) Mesangial and endocapillary proliferation (H&E stain, original magnification 100). (B) Mesangial and GBM deposits (AFOG stain, original
magnification 200). (C) Immunohistochemistry positive for C3 (original magnification 200). (D) Immunohistochemistry negative for IgG (original magnification
200). (E) EM with mostly intramembranous and mesangial not very dense electron-dense deposits (original magnification 300). (F) EM with subepithelial, intramem-
branous and subendothelial deposits (original magnification 2000).
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heterozygous mutation/deletion or variation in CFHR proteins 1,
2, 3 or 5. Recent findings show that dysregulation of the comple-
ment pathway by CFHR2–CFHR5 hybrid protein leads to
enhanced C3-convertase activation of the alternative comple-
ment pathway and other genetic complement abnormalities
associated with MPGN [12, 17, 51]. In our patients, genetic alter-
ations, including variation or polymorphisms, may at least in
part explain the different outcomes and responses to the vari-
ous treatment modalities. Similar findings are described by
other authors, where the clinical presentation and the measure-
ment of plasma C3, C3d and sC5b-9 do not allow differentiation
between C3G and MPGN I [22]. Recent knowledge suggests that
in idiopathic MPGN—an immune complex Rixensart, Belgium
mediated disease—involvement of the alternative pathway
plays an important role [17, 52].
Three of seven of our patients (two with MPGN and one with
C3GN) without nephrotic syndrome showed remission of protei-
nuria on RAAS blocker therapy only. No significant reduction in
proteinuria is described in children with MPGN treated with
RAAS blocker only. Other data revealed that patients with less
parenchymal damage in their initial renal biopsy benefit the
most from sole treatment with RAAS blocker [1]; however,
spontaneous remission may not be excluded [22]. Consistent
with other authors [1], those children of our series with neph-
rotic syndrome at onset showed a more severe course, with two
progressing to ESRD followed by RTPL.
Eculizumab has been described as a successful treatment of
patients with MPGN [35, 50, 53–55] and C3G [19, 22, 56] in several
reports. Elevated sCb5-9 levels may be a predictor of response to
treatment with eculizumab, but other factors affecting response
to therapy are poorly understood [53, 55]. Two patients of our
series, one with C3GN and one with MPGN I, exhibited a signifi-
cant decrease in proteinuria on eculizumab in their native kid-
neys, but elevated activity of the alternative pathway persisted.
This is consistent with observations of other paediatric patients
with MPGN [50] suggesting that eculizumab is not completely
effective in suppressing sC5b-9 activity in C3G. They hypothe-
sized that sC5b-9 alone may not reflect disease activity. The
presence of mutations alone does not significantly increase the
risk of developing idiopathic MPGN or C3G, but they do so when
combined with common susceptibility variants [i.e. in CD46,
CFH or Thrombomodulin (THBD)] [17, 52].
C3NeF, an auto-antibody directed against the alternative C3-
convertase, was positive at follow-up in only one child of our
series. Published reports on the impact of C3NeF on outcome in
C3G patients are inconsistent, with reported patients ranging
from complete remission to ESRD [57, 58]. Apparently C3NeF
can fluctuate during the clinical course independent of the dis-
ease treatment [22]. Others observed a higher risk of progressing
to ESRD in patients without complement gene mutation or
C3NeF, stabilizing the alternative pathway C3-convertase [52].
In our patient, C3NeF and a heterozygous variation of CFHR1
and CFHR1/3 was found. In addition, sC5b-9 was significantly
elevated. Other treatments, for example, rituximab and PEX, are
controversially discussed in the literature with different results
[52, 58, 59]. Therefore, after a risk–benefit evaluation of these
treatment options, we decided to apply eculizumab in our
young child. The outcome was favourable, with stable, normal
renal function and a significant decrease in proteinuria
11 months after eculizumab treatment was started.
In a patient undergoing RTPL twice, C3NeF and sC5b-9 were
analysed after PEX treatment with FFP had been started, so
detection of both C3NeF and sC5b-9 might have been missed
[58]. This patient experienced aABMR with recurrence of DDD 3
years after the first RTPL and was therefore treated with PEX.
However, he reached ESRD after the first RTPL, with recurrence
of the disease in the second renal graft. Treatment with PEX
was started at weekly intervals but led to only a moderate
decrease in proteinuria with persistently impaired graft func-
tion. The insurance refused to pay for treatment with
Table 3. Patients with RAAS blockers only: values at last follow-up
Characteristic Patient 1 Patient 2 Patient 3
Maintained renal function Native kidney Native kidney Native kidney
Treatment Enalapril Enalapril Enalapril
Losartan Losartan
Duration of observation (years) 9.7 2.2 4.8
eGFR 143 97 180
C3 (g/L) (reference 0.7–1.76) 0.6 <0.06 0.13
UPCR (g/mol) (reference < 20) 41 41 <20
sC3d (mU/L) (reference < 40) 50 103 35
sC5b-9 (ng/mL) (reference < 320) 239 2538 164
eGFR rate according to Schwartz formula in mL/min/1.73 m2.
Table 4. Patients with eculizumab: values before eculizumab and at
last follow-up
Characteristic (original disease)
Patient 4
(MPGN I)
Patient 5
(C3GN)
Maintained renal function Native kidney Native kidney
Additional treatments to
RAAS blockers
PDN
MMF
Before eculizumab
Duration of observation (years) 6.9 9.5
eGFR (mL/min/1.73 m2) 40 100
C3 (g/L) (reference 0.7–1.76) 0.09 0.06
UPCR (g/mol) (reference <20) 510 750
sC3d (mU/L) (reference <40) 63 95
sC5b-9 (ng/mL)
(reference >320)
4100 6500
Observation on eculizumab
Duration of therapy (months) 6 11
eGFR 45 90
UPCR (g/mol) 270 227
sC5b-9 (ng/mL) 282 639
C3 (g/L) 0.12 0.14
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eculizumab. As complement-mediated dysregulation is
involved in the pathophysiology of aABMR [60], it is conceivable
that DDD recurrence may have triggered aABMR by inducing
complement activation. In a recent study, MPGN recurrence
after RTPL was detected in 18 of 40 transplants and in 3 cases
disease recurrence preceded aABMR and led to graft loss [4].
Registries have also reported recurrence rates on renal graft for
DDD and C3G of 50% and 43–67%, respectively [22].
There are some limitations to our study: (i) its retrospective
character; (ii) the individual treatment approach based on the
clinical course; (iii) due to the different time period at disease
manifestation of each patient, no uniformity of treatment was
possible and (iv) measurement of activity of the alternative
pathway (i.e. C3d, sC5b-9) and C3NeF was not available at dis-
ease onset.
Our results reveal that early examination of the alternative
complement pathway may aid to define a more individually
tailored treatment. However, we observed heterogeneity of clin-
ical and biological features in MPGN and C3G and therefore the
difficulty of interpretation of both genetic abnormalities and
biochemical analysis. Long-term observation is necessary in
order to draw conclusions about the results of treatments and
renal function at follow-up.
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